Document:

EX-10.26

 Exhibit 10.26 

CONFIDENTIALTREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

MASTER PRECLINICAL STUDY AGREEMENT 

This MASTER PRECLINICAL STUDY AGREEMENT (this “Master Agreement”) is effective March 6, 2008,(the “Effective
Date”), between Introgen Therapeutics, Inc. (“Introgen”), and The University of Texas M. D. Anderson Cancer Center (“Institution”), a member institution of The University of Texas System
(“System”). Based upon the Background below and in consideration of the mutual promises herein and the benefits hereunder, the parties agree as follows: 

BACKGROUND 
 Introgen develops,
manufactures, distributes, and sells pharmaceutical and healthcare products. Institution is a comprehensive cancer research, treatment, and prevention center, which has on its staff certain scientists and technicians who possess unique knowledge and
experience in substantive fields relating to cancer research, and which conducts preclinical studies. Introgen and Institution desire to conduct biomedical research as applied to the prevention and treatment of cancer and therefore Introgen and
Institution are entering into this Agreement to set forth the terms and conditions under which they will undertake and perform such research. While this Master Agreement creates certain obligations between the parties, it does not obligate Introgen
to engage Institution to conduct any specific study, or, absent agreement between the parties on one or more Study Specific Agreements hereunder, obligate Institution to conduct any specific study. 

DEFINITIONS 
 “Biological Samples
Raw Data” will have the meaning ascribed to it in Section 12. 
 “Biological Materials” means cell lines,
tissue samples, probes, animal models or other living material Institution obtains outside of a Study and uses in the course of a Study. Biological Samples further include, without limitation, any tangible material directly or indirectly derived
from such blood, fluid or tissue samples, such as: genes, gene fragments, gene sequences, proteins, protein fragments, protein sequences, probes, DNA, RNA, cDNA libraries, plasmids, vectors, expression systems, cells, cell lines, organisms,
antibodies or other biological substances; and any constituents, progeny, mutants, variants, derivatives, replications, reagents or chemical compounds thereof or derived therefrom. 

“Introgen Confidential Information” means all information (including, without limitation know-how, trade secrets, or business
or research plans) of Introgen that is provided to Institution in connection with this Master Agreement, a Study Specific Agreement (as defined below), or a Study, or in connection with a planned Study which potentially could be the subject of a
Study Specific Agreement, even without an executed Study Specific Agreement. Confidential Information, however, will not include any information that: 

 (i) is or becomes publicly available, except through breach of this Master Agreement or the
relevant Study Specific Agreement; or 
 (ii) Institution can demonstrate that it possessed prior to (and without confidentiality
obligation), or developed independently from, disclosure or development under this Master Agreement or the relevant Study Specific Agreement; or 

(iii) Institution receives from a third party which is not legally prohibited from disclosing such information; or 

(iv) is generally made available to third parties by the disclosing party without restriction on disclosure. 

“Invention” means any discovery, development, invention (whether patentable or not), improvement, work of authorship,
formula, process, composition of matter, formulation, method of use or delivery, specification, computer program or model and related documentation, know-how or trade secret, that is made by a party to this Agreement or its personnel (including, in
the case of Institution, the Investigators and Study Staff) during the term of a Study, and that results from our arises out of performance of a Study. 

“Investigator” means the individual(s) responsible for the conduct of a Study at Institution and for direct supervision of
Study Staff. 
 “Materials” means Study drug(s), compounds, devices, equipment, or other materials provided by Introgen for
the conduct of a Study, together with any progeny. 
 “Protocol” means the written document that describes a Study and sets
forth specific activities to be performed as part of a Study and which will be attached to the Study Specific Agreement Form (as defined below). 

“Study” means a preclinical study supported by Introgen or that utilizes Introgen Materials and which is conducted by
Institution. 
 “Study Specific Agreement” means a written agreement between the parties that incorporates by reference the
terms of this Master Agreement and also contains terms and conditions specifically applicable to the conduct of a specific Study (see
 Attachment A). 

“Study Staff” means the individuals providing services on behalf of Institution with respect to a Study at Institution,
including without limitation subinvestigators, Study coordinators, and other Institution employees, agents, or subcontractors. 
 1.
MASTER AGREEMENT AND STUDY SPECIFIC AGREEMENTS 
 (a) If Introgen and Institution agree that Institution will conduct a Study, the
parties will enter into a Study Specific Agreement under this Master Agreement prior to conducting the Study at Institution. An executed Study Specific Agreement, along with this Master Agreement, will constitute the agreement of the parties with
respect to that Study. Where affirmatively stated in 

  
 2 

 
this Master Agreement, the parties agree that certain terms of this Master Agreement will apply without an executed Study Specific Agreement. A Study Specific Agreement form, which may be
modified by mutual agreement of the parties for specific Studies, is attached hereto as Attachment A. 
 (b) Each Study Specific
Agreement will incorporate by reference the terms of this Master Agreement, but each Study Specific Agreement will be a unique agreement and will stand alone with respect to any other Study Specific Agreement. If any provisions of a Study Specific
Agreement or a Protocol are in direct conflict with this Master Agreement so that the provisions of both cannot be given effect, the terms of the Master Agreement will govern and control. If the provisions of a Protocol are in direct conflict with a
Study Specific Agreement, the terms of the Study Specific Agreement will govern and control. 
 (c) Institution will make this Master
Agreement available to Investigators and Study Staff and require Investigators and Study Staff to comply with the provisions of this Master Agreement and the applicable Study Specific Agreement. 

2. STUDY CONDUCT 
 (a)
Institution agrees to conduct any Study in strict compliance with: 
 (i) the Study Protocol, as approved by Introgen, Investigator,
Institution and its responsible Institutional Review Board (along with any subsequently approved (by all parties) written amendments to the Study Protocol); 

(ii) all applicable local, state and federal laws, rules and regulations; 

(iii) all applicable medical privacy laws or regulations; and 

(iv) the terms of this Master Agreement and the applicable Study Specific Agreement. 

(b) Institution and Investigator will use any Materials only to conduct the Study in accordance with the Protocol; will not chemically,
physically or otherwise modify Materials, unless specifically required to do so by the Protocol; and will handle, store, and ship or dispose of Materials in compliance with all applicable local, state and federal laws, rules and regulations
including, but not limited to, those governing hazardous substances. Institution and Investigator will not charge any Study subject or third-party payor for any Materials, or for Study procedures for which payment by Introgen has or will be made
under the applicable Study Specific Agreement. 
 (c) In accordance with mutually agreed time periods, Institution will resolve all written
data queries from Introgen and will deliver to Introgen any Study-related deliverables identified in writing by Introgen and agreed to by Investigator/Institution. 

(d) Institution represents and certifies that no individual or entity will provide services on behalf of Institution in connection with a
Study if that individual or entity has been debarred under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335a(a) 

  
 3 

 
and (b) (or regulations promulgated thereunder); disqualified as a testing facility under the provisions of 21 C.F.R. Part 58, Subpart K; or disqualified as a clinical investigator
under the provisions of 21 C.F.R. § 312.70. Institution will notify Introgen of any action with respect to debarment or disqualification against Institution or any individual or entity providing services on behalf of Institution in
connection with a Study. 
 (e) Institution represents and certifies that it practices good animal care and use practices and is accredited
by the American Association for Accreditation of Laboratory Animal Care (AAALAC). Any animals that receive any of the Materials in the course of investigations or products derived from such animals will not be used for food purposes at any time. The
Materials will be used only for testing in vitro or in laboratory research animals, and not for human clinical testing. 
 (f) Subject to
compliance with confidentiality obligations under Section 7, and Introgen’s patent and other intellectual-property rights, including Introgen’s rights in Inventions under Section 9, nothing in this Master Agreement will limit or
prohibit Institution or any Study Staff, or any Investigator, from conducting any research or for performing research for or with any entity or person, including any other outside sponsors. Introgen acknowledges that this provision is intended to
preserve the academic freedom and integrity of Institution and its faculty. 
 3. COMPENSATION 

(a) In consideration for conducting a Study, Introgen will pay Institution in accordance with the terms of the applicable Study Specific
Agreement as mutually agreed upon by the parties. Introgen will have no obligation to make payments for activities or costs in the absence of an executed Study Specific Agreement or for which Introgen has not specifically agreed to pay under the
terms of the Study Specific Agreement. 
 (b) Introgen’s payment obligation is conditioned upon Institution’s compliance with
standards identified in this Master Agreement and the applicable Study Specific Agreement. 
 (c) Taxes (and any penalties and interest
thereon) imposed on any payment made by Introgen to Institution shall be the responsibility of Institution. 
 4. TERM; TERMINATION

 (a) This Master Agreement will take effect on the Effective Date and will continue in effect unless and until all Study Specific
Agreements executed within three (3) years of the Effective Date have expired or been terminated, unless this Master Agreement is earlier terminated as provided below. Each Study Specific Agreement will take effect as of an effective date
designated in the Study Specific Agreement. Termination of this Master Agreement will include termination of all Study Specific Agreements that are entered into under this Master Agreement, but termination of any Study Specific Agreement will not
affect any other Study Specific Agreement; each Study Specific Agreement will continue in full force and effect unless specifically terminated in accordance with the terms of this Master Agreement or the terms of that Study Specific Agreement. 

  
 4 

 (b) Either party may terminate this Master Agreement, without cause, upon sixty (60) days
written notice, subject to Section 5(a). 
 (c) Either party may terminate this Master Agreement upon written notice to the other party
if the other party fails to remedy a material breach of this Master Agreement (provided the material breach applies generally to all Study Specific Agreements entered into under this Master Agreement) within thirty (30) days after written
notice of the material breach. 
 (d) Either party may terminate this Master Agreement or any Study Specific Agreement immediately upon
written notice if proceedings are instituted against the other party for reorganization or other relief under any bankruptcy law which proceedings are not dismissed within one hundred and twenty (120) days, or if any substantial part of the
other party’s assets come under the jurisdiction of a receiver or trustee in an insolvency proceeding authorized by law. 
 (e)
Introgen may terminate any Study Specific Agreement, in whole or in part, without cause, upon sixty (60) days prior written notice to Institution. Written notice by Introgen that a Study is terminated will also constitute effective notice of
termination of the applicable Study Specific Agreement. Either party may terminate any Study Specific Agreement upon written notice to the other party if the other party fails to remedy a material breach of the Study Specific Agreement (including a
material breach of this Master Agreement in relation to the Study Specific Agreement) within thirty (30) days after written notice of the material breach. 

(f) Either party may terminate a Study Specific Agreement immediately for safety, regulatory or ethical reasons, or if the Investigator is no
longer employed by Institution or is no longer able to perform the Study due to family, health, or medical reasons. Upon any such immediate termination event, the party which has terminated the Study Specific Agreement will provide prompt notice of
the termination of the Study Specific Agreement to the other party, provided, however, that if the Investigator is no longer employed by Institution or is no longer able to perform the Study due to family, health, or medical
reasons, then, before terminating the Study Specific Agreement, Institution will make a good faith effort to first find a substitute researcher who is ready, willing and able to assume the role of Investigator and complete the Study and who is
acceptable to Introgen. 
 5. EFFECT OF TERMINATION 

(a) If Institution terminates this Master Agreement by written notice to Introgen under Section 4(b), and if as of Institution’s
notice-of-termination date there are any Study Specific Agreements in effect under which any Studies are on-going, then at Introgen’s option Institution shall be required to complete the performance of such Studies under the terms of this
Master Agreement, with termination of this Master Agreement (and such Study Specific Agreements) taking effect only upon Institution’s completion of the Studies, subject to Sections 4(c) – 4(f). 

(b) Upon written notice of termination of a Study Specific Agreement by either Institution or Introgen, Institution will, subject to
Section 5(a) solely in the event of termination by Institution under Section 4(b), discontinue conduct of the Study; provided however, that upon Introgen’s request, the Institution and the Investigator shall continue to collect data
prior to termination. 

  
 5 

 (c) Upon written notice of termination of a Study Specific Agreement by either Institution or
Introgen, Institution will, subject to Section 5(a) solely in the event of termination by Institution under Section 4(b), use reasonable efforts to revoke any financial obligations incurred and will avoid incurring any additional costs in
connection with the Study. Institution will be compensated only for Study-related work actually performed and reimbursed only for expenses actually and reasonably incurred through the effective date of termination that Introgen has agreed to pay as
part of a Study under the applicable Study Specific Agreement. If, upon the effective date of termination, Introgen has advanced funds which are unearned by Institution, Institution will repay such funds within sixty (60) days of the effective
date of termination. 
 (d) Upon termination of a Study Specific Agreement, all unused Materials and all Introgen Confidential Information
in Institution’s possession will be promptly delivered to Introgen at Introgen’s expense, or, at Introgen’s option, destroyed with the destruction certified in writing. Further, upon termination of a Study Specific Agreement, the
Institution and the Investigator shall provide to Introgen all data collected in connection with the Study. 
 (e) Sections 5, 6, 7, 8,
9, 10, 11, 12, 14, 15, 19 and 21 shall survive the expiration or termination of this Agreement. 
 6. RESULTS; RECORDKEEPING; ACCESS

 (a) Within thirty (30) days following the earlier of completion or termination of each Study, Investigator will provide to
Introgen a written report summarizing the results of the research included within the scope of the Study, including but not limited to all data, conclusions, results, observations and a detailed description of all procedures (collectively, the
“Results”). Subject to Institution’s rights set forth in Section 9 and Institution’s patent and other intellectual property rights, Introgen may use and disclose the Results in furtherance of its own research, development
and commercialization activities, including without limitation in support of Introgen’s patent applications or in preparing regulatory filings, without additional compensation to Institution. 

(b) Institution, Investigator and other personnel assisting in the Studies will make and retain complete and current written records to
accurately reflect all research performed in each Study, which shall include laboratory notebooks that document such research created in the course of the Studies, all in accordance with 21 C.F.R. § 312.62 and applicable law or guidelines.
Study record storage by Institution for up to five (5) years past the time required by applicable FDA regulations will, for the period following the termination or expiration of the relevant Study Specific Agreement, be subject to reasonable
storage fees paid by Introgen. Notwithstanding the foregoing, Institution will not destroy such records without giving Introgen prior written notice and the opportunity to further store such records at Introgen. 

(c) Authorized representatives of Introgen, upon reasonable advance written notice and during regular business hours, will have the right to
inspect Institution’s facilities used in the conduct of a Study and to inspect and copy (if authorized and legal) all records directly relating 

  
 6 

 
to a Study (including, without limitation, access to records as necessary for Study monitoring or to audit the conduct of a Study in accordance with Introgen standards). Introgen’s access to
Institution’s facilities, however, will be subject to Institution’s reasonable measures for purposes of confidentiality, safety, and security, and will be subject further to compliance with Institution’s premises rules that are
generally applicable to all persons at Institution’s facilities. 
 (d) If any governmental or regulatory authority notifies
Institution that it will inspect Institution’s records, facilities, equipment, or procedures, or otherwise take action related to a Study, then, to the extent permitted by law, Institution will promptly notify Introgen, allow Introgen to be
present at the inspection/action or participate in any response to the inspection/action, and provide Introgen with copies of any reports issued by the authority and Institution’s proposed response. 

(e) The parties agree that obligations under this Section may exist without an executed Study Specific Agreement. The obligations of this
Section will survive termination of this Master Agreement and any applicable Study Specific Agreement. 
 7. CONFIDENTIALITY

 (a) Introgen Confidential Information and all tangible expressions, in any media, of Introgen Confidential Information are the sole
property of Introgen (excluding works of authorship notwithstanding Section 8). Introgen will endeavor to identify tangible Confidential Information provided to Institution as “Confidential” given the understanding that failure to do
so does not constitute a designation of non-confidentiality when the confidential nature is apparent from context and subject matter. Institution agrees to treat Introgen’s Confidential Information as it would its own proprietary and
confidential information. Institution will only accept information from Introgen which is required for conduct of a Study and which must be maintained for Institution’s records. The Principal Investigator reserves the right to refuse to accept
any Confidential Information s/he does not consider to be essential to the performance of a Study. 
 (b) Institution agrees not to use
Introgen Confidential Information for any purposes other than to conduct the Study. Institution agrees not to disclose Introgen Confidential Information to third parties except as necessary to conduct a Study and under an agreement by the third
party to maintain the confidentiality of such information consistent with the confidentiality obligations of this Section. Institution will safeguard Introgen Confidential Information with the same standard of care that is used with
Institution’s Confidential Information, but in no event less than reasonable care. The parties understand and agree that information communicated to Institution’s scientific and/or institutional review committees is confidential. 

(c) The obligations of confidentiality and limited use under this Section will not prohibit Institution from disclosing Introgen
Confidential Information to the extent such Introgen Confidential Information: 
 (i) is necessary in order to seek or enforce a patent on
any Invention hereunder provided, however, that the Institution (a) to the extent reasonably possible, prior to disclosure, will allow Introgen to review Confidential Information to be disclosed and to challenge

  
 7 

 
the need for such disclosure; (b) will disclose Confidential Information only to the extent necessary; and (c) in any enforcement action, will make reasonable efforts to limit public
disclosure by seeking a protective order or other appropriate protection with respect to such disclosure; 
 (ii) is required to be
communicated to Institution’s scientific and/or institutional review committees, provided, however, that the members of such committees are obligated to maintain the confidentiality of the information; or 

(iii) is required to be disclosed by applicable law (including statute, rule, regulation, order, or other legal compulsion) or proper legal,
governmental, or other competent authority; provided that to the extent reasonably possible Institution will notify Introgen in writing of the required disclosure sufficiently in advance of such disclosure so that Introgen may seek a protective
order or other appropriate protection with respect to such disclosure, which Institution will fully comply with); or 
 (iv) is permitted
to be included in an Institution Publication (as defined below) in accordance with Section 8 of this Master Agreement. 
 (d)
Notwithstanding any other provision of this Agreement, if either party obtains any health or medical information of any Study subject, the party will hold in confidence the identity of the subject and the health/medical information and will comply
with applicable laws and policies regarding the confidentiality of such information. The parties agree that obligations under this Section may exist without an executed Study Specific Agreement. The obligations of this Section will survive
termination of this Master Agreement and any applicable Study Specific Agreement. 
 8. PUBLICATION 

(a) Notwithstanding any other provision of this Agreement, Institution and Investigator, consistent with scientific standards and in a
scientific forum, may publish, present or post to a public data registry the Study results from Institution’s Study data (an “Institution Publication”), provided that the Institution Publication does not also disclose any
Introgen Confidential Information without Introgen’s prior written consent. Institution and Investigator will submit to Introgen for review and comment any proposed Institution Publication at least sixty (60) days prior to submitting the
Institution Publication to any third party. If Introgen requests a delay in order to file patent applications relating to an Invention, Institution agrees to and Investigator will delay submitting the Institution Publication to any third party for,
as required by Introgen, up to an additional sixty (60) days. 
 (b) The obligations of this Section will survive termination of
this Master Agreement and any applicable Study Specific Agreement. 
 9. INTELLECTUAL PROPERTY 

(a) As between the parties, Introgen shall own all right, title and interest in and to the Materials. 

  
 8 

 (b) Subject to Section 9(a): (i) Institution shall own all right, title and interest in
and to any Inventions conceived or first reduced to practice by its personnel (including Investigators and Study Staff) during the term of this Agreement, to the extent that such personnel would be an inventor thereof under U.S. patent law
(“Institution Inventions”), (ii) Introgen shall own all right, title and interest in and to any Inventions conceived or first reduced to practice by its personnel during the term of this Agreement, to the extent that such personnel
would be an inventor thereof under U.S. patent law (“Introgen Inventions”), and (iii) patent rights to Inventions that are made jointly by personnel of Introgen and Institution (“Joint Inventions”) shall be owned jointly.
For purposes of this Section 9(b), whether an Invention is made “jointly” shall be determined under principles of inventorship in accordance with U.S. patent law, and “joint ownership” means that, subject to the rights of
Introgen under Section 9(f), each party is free to exploit such patent rights and authorize others to do so, with no obligation to account to the other party, for profits or otherwise. 

(c) Institution will notify Introgen, promptly, in writing, and on a confidential basis, of any Institution Invention or Joint Invention
disclosed to its Office of Technology Commercialization. Similarly, Introgen will notify Institution, promptly, in writing and on a confidential basis of any Introgen Invention or Joint Invention that is disclosed to Introgen’s patent counsel.

 (d) Institution represents and certifies that its Investigators and Study Staff are required to disclose inventions to Institution.
Institution will cause Investigators and Study Staff to assign to the Board of Regents of System, all of their right, title and interest in each Institution Invention and Joint Invention. 

(e) Without limiting Introgen’s rights under Sections 9(0 or 9(g), Institution hereby grants to Introgen a worldwide, non-exclusive,
royalty-free, perpetual, irrevocable license to Institution Inventions for Introgen’s internal research purposes. Such license includes the right to have a third party practice any Institution Inventions on behalf of Introgen that advance
Introgen’s internal research activities. 
 (f) Institution grants to Introgen an option to obtain, on commercially reasonable terms,
either, at Introgen’s election (i) a worldwide, royalty-bearing, exclusive license to Institution Inventions and Joint Inventions, or (ii) a worldwide, royalty-bearing, nonexclusive license to Institution Inventions, Introgen shall
have three (3) months from the written disclosure of any such Invention to review such disclosure, to reasonably request additional information from Institution with respect to the disclosure, and to notify Institution of its desire to enter
into an exclusive license agreement (or at Introgen’s election, a nonexclusive license agreement) (the “Option Term”). Upon such notice from Introgen, the parties shall negotiate an exclusive (or at Introgen’s election, a
non-exclusive) license to such Invention in good faith for a period not to exceed six (6) months from Introgen’s notification, or such period of time as to which the parties shall mutually agree; and (1) if Introgen elects to obtain
an exclusive license, then (a) such exclusive license shall substantially be in the form of the exclusive license agreement attached and incorporated into this Agreement as Attachment B-1 unless the Invention includes the transfer of materials,
in which case additional changes will be made as reasonably required, and (b) amounts payable by Introgen under the exclusive license shall be consistent with the terms set forth in Attachment C-1, and (2) if Introgen

  
 9 

 
elects to obtain a non-exclusive license, then (y) such non-exclusive license shall substantially be in the form of the non-exclusive license agreement attached and incorporated into this
Agreement as Attachment B-2 unless the Invention includes the transfer of materials, in which case additional changes will be made as reasonably required, and (z) amounts payable by Introgen under the non-exclusive license shall be consistent
with the terms set forth in Attachment C-2. 
 (g) If the parties, after making good-faith efforts, are unable to agree upon the terms for
the exclusive or non-exclusive license under Section 9(0, then either party may, by written notice to the other, submit the matter for settlement pursuant to this Section 9(g); provided that Institution shall have no right to initiate such
dispute-resolution procedures where Introgen agrees to pay the maximum amounts set forth on Attachment C. 
 (i) First, either Introgen or
Institution may, by written notice to the other, have such dispute referred to a senior executive of each party for attempted resolution by good faith negotiations for a period of fifteen (15) days after such notice is received. Unless
otherwise mutually agreed, the negotiations between the designated officers shall be conducted by telephone as soon as possible, and at times within the period stated above. Subject to Section 9(g)(ii), if the parties are unable to resolve such
dispute in accordance with the aforementioned procedure or within such fifteen (15)-day period, either party may pursue any and all other remedies available to such party. 

(ii) Second, if the parties, after making good-faith attempted resolution under Section 9(g)(i), are unable to agree upon the terms for
the exclusive or non-exclusive license, then either party may initiate resolution of the dispute through mediation of the dispute sending written notice of the dispute, and an intent to mediate the dispute under this Section 9(g)(ii) to the
other party. In any such mediation, the mediator shall be an independent expert in worldwide pharmaceutical product development (including in the area of the dispute) mutually acceptable to the parties. Any such mediation shall be completed within
thirty (30) days following a request by any party for such mediation. 
 (h) Upon Introgen’s written request, Institution will
execute and will use reasonable efforts to cause Investigators and Study Staff to execute any instruments reasonably necessary to obtain patents or take other reasonable acts to protect Introgen’s interest in an Invention. Introgen will
reasonably compensate Institution for the time devoted to such activities and will reimburse Institution for reasonable and necessary expenses incurred. 

(i) The obligations of this Section will survive termination of this Master Agreement and any applicable Study Specific Agreement. 

10. INDEMNIFICATION AND LIABILITY 

(a) Introgen agrees to indemnify, defend and hold harmless Institution and System and their Board, Investigators, Study Staff, and other
employees, officers, agents, and subcontractors (“Institution Indemnitees”) from and against any third-party claim, and any resultant loss, expense, cost (including reasonable attorneys fees), liability or damage, that arises out of
the activities to be carried out by Institution pursuant to the obligations of this Agreement, including but not limited to the use by Introgen of the results obtained from the activities performed by Institution

  
 10 

 
under this Agreement; (“Institution Claim”), provided that Introgen will not indemnify any Institution Indemnitee for any Institution Claim to the extent the Institution Claim
arose out of: 
 (i) failure by Institution Indemnitees to conduct a Study in accordance with the Protocol, GCPs, Introgen’s written
instructions or written warnings (including package inserts, where appropriate), or applicable laws or regulations; 
 (ii) the negligence
or willful misconduct of Institution Indemnitees; or 
 (iii) a breach by Institution Indemnitees of this Master Agreement or the
applicable Study Specific Agreement. 
 (b) To the extent authorized by the Constitution and laws of the State of Texas and subject to the
statutory duties of the Texas Attorney General, Introgen’s obligations under this Section with respect to an Institution Claim are conditioned on: 

(i) prompt written notification to Introgen of the Institution Claim so that Introgen’s ability to defend or settle the Institution
Claim is not adversely affected, provided, however, that any delay in providing notice of a claim to Introgen will not relieve Introgen of its indemnification obligation hereunder unless the delay materially and adversely
affects Introgen’s ability to defend against the claim; and 
 (ii) subject to the statutory duties of the Texas Attorney General,
Introgen has sole control over the defense or settlement of the Institution Claim and subject to the statutory duties of the Texas Attorney General, Institution will fully cooperate with Introgen in the defense or settlement of the Institution
Claim; provided, that, no Institution Indemnitee will be required to admit fault or responsibility in connection with any settlement or financially contribute to the Settlement. 

(c) To the extent authorized by the Constitution and the laws of the State of Texas, Institution agrees to indemnify, defend and hold harmless
Introgen and its employees, agents, and subcontractors (“Introgen Indemnitees”) from and against any loss, expense, cost (including reasonable attorneys fees), liability, damage, or claim by third parties for personal injury,
including death, resulting from (1) failure by Institution Indemnitees to conduct a Study in accordance with the Protocol, GCPs, Introgen’s written instructions or written warnings (including package inserts, where appropriate), or
applicable laws or regulations, (2) the negligent acts or omissions, or willful misconduct, of Institution Indemnities, including but not limited to, Investigators, or Study Staff, pertaining to the activities to be carried out pursuant to the
obligations of this Master Agreement or the applicable Study Specific Agreement, or (3) a breach by Institution Indemnitees of this Master Agreement or the applicable Study Specific Agreement (“Introgen Claim”), provided that
Institution will not indemnify any Introgen Indemnitee for any Introgen Claim to the extent the Introgen Claim arose out of: 
 (i) the
negligence or willful misconduct of Introgen Indemnitees; or 

  
 11 

 (ii) a breach by Introgen Indemnitees of this Master Agreement or the applicable Study Specific
Agreement. 
 (d) Institution’s obligations under this Section with respect to an Introgen Claim are conditioned on: 

(i) prompt written notification to Institution of the Introgen Claim so that Institution’s ability to defend or settle the Introgen
Claim is not adversely affected, provided, however, that any delay in providing notice of a claim to Institution will not relieve Institution of its indemnification obligation hereunder unless the delay materially and adversely
affects Institution’s ability to defend against the claim; and 
 (ii) Introgen Indemnitees’ agreement that, subject to the
statutory duties of the Texas Attorney General, Institution has sole control over the defense or settlement of an Introgen Claim and, subject to the statutory duties of the Texas Attorney General, to fully cooperate with Institution in the defense
or settlement of an Introgen Claim; provided, that, no Introgen Indemnitee will be required to admit fault or responsibility in connection with any settlement or financially contribute to a settlement. 

(e) The Material is experimental in nature and it is provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY
OTHER WARRANTY, EXPRESS OR IMPLIED, and INTROGEN SPECIFICALLY MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT, However, Introgen represents and warrants that as of the
Effective Date of this Agreement it has no actual knowledge and has not received any written notice that the use of any Material hereunder infringes any patent or other proprietary right, and that during the term of this Agreement it will use
commercially reasonable efforts to notify Institution of any such knowledge or notice that it receives after the Effective Date of this Agreement. In no event shall Introgen be liable for any use by Investigator or Institution of the Material for
any loss, claim, damage or liability, of whatsoever kind or nature, which may arise from or in connection with this Agreement or the use, handling or storage of the Material. 

(f) The obligations of this Section will survive termination of this Master Agreement and any applicable Study Specific Agreement. 

11. INSURANCE 
 (a)
Institution, as a component of System, is an agency of the State of Texas and is self-insured pursuant to The University of Texas System Professional Medical Malpractice Self-Insurance Plan, under the authority of Section 59.01, Texas Education
Code. Institution has and will maintain in force during the term of this Agreement (and for a period of seven (7) years thereafter) adequate insurance or financial resources to cover its indemnification obligations hereunder. 

(b) Introgen has and will maintain in force during the term of this Agreement, and during the period that Introgen uses the results of the
Studies or Inventions, comprehensive general 

  
 12 

 
liability insurance in amounts not less than $2,000,000.00 per incident or equivalent self insurance. Such insurance will provide (1) product liability coverage and (2) broad form
contractual liability coverage. Upon written request, Introgen will provide Institution with written evidence of its self-insurance program. 

12. BIOLOGICAL SAMPLES 

To the extent that any Biological Materials are transferred from Institution to Introgen pursuant to a Study, Introgen agrees that it will only
use those Biological Materials to conduct Study activities and will not use the Biological Materials for any other purpose. Introgen will disclose to the Principal Investigator any raw data generated by Introgen from its research using such
Biological Materials that directly and solely relates to the Biological Materials (“Biological Samples Raw Data”). Institution will treat such Biological Samples Raw Data as Introgen’s Confidential Information under this Master
Agreement. Notwithstanding the foregoing, Institution may use the Biological Samples Raw Data in support of publications (with Introgen’s prior written consent, not to be unreasonably withheld or delayed) and for internal, non-commercial
research and academic purposes. In the event that the Principal Investigator desires to conduct research outside of a specific Study in collaboration with Introgen with respect to such Biological Samples Raw Data, Introgen agrees to consider any
such request. Any such research agreed upon by Introgen will be subject to the terms of a separate Study Specific Agreement. Additionally, upon prior written notice to Introgen, Institution may disclose such Biological Samples Raw Data to academic
investigators for non-commercial research and academic purposes, provided, however, that prior to such disclosure, the Institution has published the results relating to the Biological Samples Raw Data and, to the extent that the Biological Samples
Raw Data was not required to be made publicly available in conjunction with any such publication, has executed an agreement with the recipient that identifies such Biological Samples Raw Data as Introgen’s Confidential Information and binds the
recipient to keep such Biological Samples Raw Data confidential. 
 13. INDEPENDENT CONTRACTOR 

The relationship of the parties is that of independent contractors. Neither party is the partner, joint venturer, or agent of the other and
neither party has authority to make any statement, representation, commitment, or action of any kind which purports to bind the other without the other’s prior written authorization. 

14. USE OF PARTIES’ NAME 

Except to the extent required by law or regulation, or academic or publishing policy, or solely for purposes of identifying and describing a
party’s role in a Study in any publication of the results of a Study (subject to Section 8), neither party will make (or have made on its behalf) any oral or written release of any statement, information, advertisement or publicity in
connection with this Master Agreement, any Study Specific Agreement, or a Study, which uses the other party’s name, symbols, or trademarks without the other party’s prior written approval which will not be unreasonably withheld. For
clarity, it is understood and agreed that Introgen may disclose the performance of the Studies hereunder, by naming Institution and/or the Investigator, to its potential investors and collaborators on a need-to-know basis, or as otherwise permitted
under this Agreement. 

  
 13 

 15. NOTICES 

All notices under this Master Agreement or a Study Specific Agreement will be sent by registered or certified mail, postage prepaid, or by
overnight courier service. Notices pertaining to this Master Agreement or a Study Specific Agreement must be sent to the parties at the following addresses: 

If to Institution: 
 The
University of Texas M. D. Anderson Cancer Center 
 1515 Holcombe Blvd., Unit 537 

Houston, Texas 77030 
 Attention:
Chief Legal Officer 
 cc: Christopher C. Capelli, Vice President, Technology Based Ventures 

If to Introgen: 
 Introgen
Therapeutics, Inc. 
 2250 Holcombe Blvd., Unit 537 

Austin, Texas 77030 
 Attention:
David Enloe 
 or any other address that may be given from time to time under the terms of this Section 15. 

16. ASSIGNMENT 
 Neither
party may assign this Master Agreement without the other party’s prior written consent, which will not be unreasonably withheld, except that Introgen may assign its rights and obligations under this Master Agreement to any successor in interest
to all or substantially all of the business to which this Master Agreement relates so long as such assignee expressly assumes this Master Agreement and is bound to perform the obligations of Introgen hereunder. To the extent permitted above, this
Master Agreement and each Study Specific Agreement will be binding upon and inure to the benefit of the parties and their permitted successors and assigns. 

17. SEVERABILITY 
 If any
provision(s) of this Master Agreement or a Study Specific Agreement should be illegal or unenforceable in any respect, the legality and enforceability of the remaining provisions of this Master Agreement or the Study Specific Agreement will not be
affected. 
 18. WAIVER; MODIFICATION OF AGREEMENT 

No waiver, amendment, or modification of any of the terms of this Master Agreement or a Study Specific Agreement will be valid unless in
writing and signed by authorized representatives of 

  
 14 

 
both parties. Failure by either party to enforce any rights under this Master Agreement or a Study Specific Agreement will not be construed as a waiver of such rights nor will a waiver by either
party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances. 
 19. GOVERNING LAW

 This Master Agreement and any Study Specific Agreement will be governed by and interpreted in accordance with the laws of the State of
Texas. 
 20. ENTIRE AGREEMENT 

This Master Agreement, in conjunction with individual Study Specific Agreements entered into under this Master Agreement, represents the entire
and integrated agreement between the parties and supersedes all prior negotiations, representations or agreements, either written or oral, regarding its subject matter. This Master Agreement and any Study Specific Agreement may be executed in one or
more counterparts, each of which will be deemed an original and all of which will constitute the same instrument. 
 21. CONFORMANCE WITH
AND SUBORDINATION OF LAW 
 (a) The parties acknowledge that Institution is an agency of the State of Texas and under the Constitution
and laws of the State of Texas possesses certain rights and privileges and only such authority as is granted to it under the Constitution and laws of the State of Texas. Notwithstanding any provision hereof, nothing herein is intended to be, nor
will it be construed to be, a waiver of the sovereign immunity of the State of Texas or a prospective waiver or restriction of any of the rights, remedies, claims, and privileges of the State of Texas. Moreover, notwithstanding the generality or
specificity of any provision hereof, the provisions of this Master Agreement as they pertain to Institution are enforceable only to the extent authorized by the Constitution and laws of the State of Texas. 

(b) Institution will not be required to perform any act or to refrain from any act that would violate any state or federal law. In this
regard, this Master Agreement is subject to, and the parties agree to comply with, all applicable local, state, and federal laws, statutes, rules, and regulations, and all applicable judicial or administrative orders. Any provision or any law,
statute, rule, regulation, or order that invalidates any provision of this Master Agreement, that is inconsistent with any provision of this Master Agreement, or that would cause one or both of the parties hereto to be in violation of law will be
deemed to have superseded the terms of this Master Agreement. The parties, however, will use their reasonable efforts to accommodate the terms and intent of this Master Agreement to the greatest extent possible consistent with the requirements of
the law and negotiate in good faith toward amendment of this Master Agreement in such respect. 
 IN WITNESS WHEREOF, the parties have
caused this duly authorized representative to execute this Master Agreement. 

  
 15 

							
	INTROGEN THERAPEUTICS, INC.	    	THE UNIVERSITY OF TEXAS
		 		    	M. D. ANDERSON CANCER CENTER
				
	By:	 	 /s/ David Enloe
	    	By:	 	 /s/ Wesley Harrott

		 	Name: David Enloe Jr.	    		 	Name: Wesley Harrott
		 	Title: Sr. VP, Operations	    		 	Title: Executive Director for Research Administration
				
		 	Date: 3/6/08	    		 	Date: 1/7/08

  
 16 

 Exhibit A 

Protocol 

  
 17 

 Exhibit B 

Payment Schedule 

  
 18 

 Attachment B-1 

Form of Exclusive License Agreement 

  
 1 

 EXCLUSIVE PATENT AND TECHNOLOGY LICENSE AGREEMENT 

This             (    ) page AGREEMENT (“AGREEMENT”)
is made on this              day of                     , 200  , by and between
THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM (“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER
CENTER (“UTMDACC”), a component institution of SYSTEM, and Introgen Therapeutics, Inc., a Texas corporation having a principal place of business located at 301 Congress, Suite 1850, Austin, Texas 78701 (“LICENSEE”). 

RECITALS 
 A. BOARD owns
certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to LICENSED SUBJECT MAI [ER developed at UTMDACC. 
 B. BOARD, through UTMDACC, desires
to have the LICENSED SUBJECT MATTER developed in the LICENSED FIELD and used for. the benefit of LICENSEE, BOARD, SYSTEM, UTMDACC, the inventor(s), and the public as outlined in BOARD’s Intellectual Property Policy. 

C. LICENSEE wishes to obtain a license from BOARD to practice LICENSED SUBJECT MATTER. 

NOW, THEREFORE, in consideration of the mutual covenants and promises herein contained, the parties agree as follows: 

I. EFFECTIVE DATE 
 1.1
This AGREEMENT is effective as of the date of final execution of this AGREEMENT (“EFFECTIVE DATE”). 

  
 1 

 II. DEFINITIONS 

As used in this AGREEMENT, the following terms have the meanings indicated: 

2.1 AFFILIATE means any business entity more than fifty percent (50%) owned by LICENSEE, any business entity which owns more than fifty
percent (50%) of LICENSEE, or any business entity that is more than fifty percent (50%) owned by a business entity that owns more than fifty percent (50%) of LICENSEE. 

2.2 LICENSED FIELD means all fields of use. 

2.3 LICENSED PRODUCTS means any product or service sold by LICENSEE, its AFFILIATES or SUBLICENSEES comprising LICENSED SUBJECT MATTER
pursuant to this AGREEMENT. 
 2.4 LICENSED SUBJECT MATTER means inventions and discoveries covered by PATENT RIGHTS or TECHNOLOGY
RIGHTS within LICENSED FIELD. 
 2.5 LICENSED TERRITORY means worldwide. 

2.6 MAJOR MARKET COUNTRIES means, collectively, all of the United States, Japan and at least four of the following countries in Europe:
United Kingdom, France, Germany, Spain, Italy, Sweden and Switzerland. 
 2.7 NET SALES means the gross revenues received by
LICENSEE, its AFFILIATES or SUBLICENSEES from a SALE less sales discounts actually granted, sales and/or use taxes actually paid, import and/or export duties actually paid, outbound transportation actually prepaid or allowed, and amounts actually
allowed or credited due to returns (not exceeding the original billing or invoice amount), all as recorded by LICENSEE, AFFILIATES or SUBLICENSEES in their official books and records in accordance with generally accepted accounting practices and
consistent with their published financial statements and/or regulatory filings with the United States Securities and Exchange Commission. 

  
 2 

 2.8 PATENT RIGHTS means (a) all of BOARD’s rights in and to any patents and
patent applications, whether domestic or foreign, that claim any invention, information or discovery described in any of the invention disclosures defined in Exhibit I attached hereto, including the patent application listed in Exhibit I,
and all patents, whether domestic or foreign that issue thereon; and (b) all divisionals, continuations, continuations-in-part (to the extent the claims of such continuations-in-part are entitled to claim priority to the aforesaid patents
and/or patent applications defined in clause (a)), reissues, reexaminations or extensions of the patents and patent applications defined in clause (a), and any letters patent, domestic or foreign that issue thereon. From time to time during the term
of this AGREEMENT, upon request by either party, LICENSEE and BOARD shall promptly update Exhibit I to include all patent applications and patents that are within PATENT RIGHTS. 

2.9 SALE or SOLD means the transfer or disposition of a LICENSED PRODUCT for value (or, with respect to LICENSED PRODUCTS that
are services, the provision of such services for value on a fee-for-services basis) to a party other than LICENSEE, {or} an AFFILIATE{Add the bold sections if one or more inventors are MDs:. or a ROYALTY-FREE PRACTITIONER. As used herein,
“ROYALTY-FREE PRACTITIONER” means UTMDACC and              (the “PHYSICIAN INVENTOR”), and any partner or associate who practices medicine with one or more of the
PHYSICIAN INVENTOR, but with respect to such partner or associate, only for such time as they are engaged in a bona fide medical practice with one or more of the PHYSICIAN INVENTOR.] 

  
 3 

 2.10 SUBLICENSEE means any third party to whom LICENSEE has granted a sublicense under the
LICENSED SUBJECT MATTER to make and sell LICENSED PRODUCTS, with respect to LICENSED PRODUCTS made and sold by such SUBLICENSEE. As used herein, “SUBLICENSEE” shall also mean a third party to whom LICENSEE has granted the exclusive right
to distribute LICENSED PRODUCTS supplied by LICENSEE, provided that such third party is responsible for all marketing and promotion of the subject LICENSED PRODUCTS within its exclusive territory. 

2.11 SUBLICENSE INCOME means all consideration received by LICENSEE from a SUBLICENSEE in consideration of a sublicense of the LICENSED
SUBJECT MATTER, including but not limited to, up-front payments, marketing, distribution, franchise, option, license, or documentation fees, bonus and milestone payments and equity securities. SUBLICENSE INCOME shall specifically exclude:
(i) payments received by LICENSEE from a sublicense as a result of the purchase or sale of debt or equity securities of LICENSEE by such sublicense, and (ii) payments for research and development of the LICENSED PRODUCTS; and
(iii) any royalties that LICENSEE receives for the SUBLICENSEE’s sale of LICENSED PRODUCTS (which are captured under Section 4.1(d)). 

2.12 TECHNOLOGY RIGHTS means BOARD’s rights in any technical information, know-how, processes, procedures, compositions, devices,
methods, formulae, protocols, techniques, software, designs, drawings or data created by the inventor(s) listed in Exhibit I, or those working in the lab or under the supervision or direction of one or more of the inventor(s) listed in
Exhibit I, at UTMDACC before the EFFECTIVE DATE, whether or not claimed in PATENT RIGHTS but that are reasonably necessary for practicing an invention at any time claimed in the PATENT RIGHTS. 

  
 4 

 2.13 VALID CLAIM means either (a) a claim of an issued and unexpired patent included
within the PATENT RIGHTS which has not been held unenforceable, unpatentable or invalid by the final decision of a court or other governmental agency of competent jurisdiction, in which such decision is unappealable or unappealed within the time
allowable for appeal, and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a pending claim in a patent application within the PATENT RIGHTS, provided that if such pending claim has not
issued as a claim or an issued patent within the PATENT RIGHTS within five (5) years after the filing of the application in which such claim first appears, such pending claim shall not be a VALID CLAIM for purposes of this AGREEMENT, unless and
until subsequent to such five (5) year period, such pending claim is issued as a claim of an issued and unexpired patent included within the PATENT RIGHTS as set forth in (a) above. 

III. LICENSE 
 3.1 BOARD,
through UTMDACC, hereby grants to LICENSEE a royalty-bearing, exclusive license under LICENSED SUBJECT MATTER to manufacture, have manufactured, use, import, offer to sell and/or sell LICENSED PRODUCTS, to practice any method, process or procedure
and to otherwise exploit the LICENSED SUBJECT MATTER, in each case within LICENSED TERRITORY for use within. LICENSED FIELD. This grant is subject to Sections 14.2 and 14.3 herein below, the payment by LICENSEE to UTMDACC of all consideration
as provided herein, and is further subject to the following rights retained by BOARD and UTMDACC to: 
 (a) Publish the general scientific
findings from research related to LICENSED SUBJECT MATTER, subject to the terms of Article XI—Confidential Information and Publication; and 

  
 5 

 (b) Use LICENSED SUBJECT MATTER for research, teaching, patient care, and other
educationally-related purposes; and 
 (c) Transfer LICENSED SUBJECT MATTER to academic or research institutions for non-commercial research
use. 
 3.2 LICENSEE may extend the license granted herein to any AFFILIATE provided that the AFFILIATE consents in writing to be bound by
this AGREEMENT to the same extent as LICENSEE. LICENSEE agrees to deliver such contract to UTMDACC within thirty (30) calendar days following execution thereof. 

3.3 LICENSEE may grant and authorize sublicenses under LICENSED SUBJECT MATTER consistent with the terms of this AGREEMENT. LICENSEE is
responsible to use commercially reasonable efforts to cause its SUBLICENSEES to comply with the relevant obligations under this AGREEMENT, and for diligently collecting all amounts due LICENSEE from SUBLICENSEES. If a SUBLICENSEE pursuant hereto
becomes bankrupt, insolvent or is placed in the hands of a receiver or trustee, LICENSEE, to the extent allowed under applicable law and in a timely manner, agrees to use its reasonable efforts to collect all consideration owed to LICENSEE and to
have the sublicense agreement confirmed or rejected by a court of proper jurisdiction. 
 3.4 LICENSEE must deliver to UTMDACC a true and
correct copy of each sublicense granted by LICENSEE, and any modification or termination thereof, within thirty (30) calendar days after execution, modification, or termination. 

3.5 If this AGREEMENT is terminated pursuant to Article XI-Term and Termination, all sublicenses granted hereunder that are in compliance with
their terms shall survive the termination provided that each such SUBLICENSEE consents in writing to be bound directly to BOARD and UTMDACC to all of the terms and conditions of this AGREEMENT, subject to any field of use or

  
 6 

 
jurisdictional limitations provided in the original sublicense; provided that in such case the SUBLICENSEE’s obligation to pay the costs of searching, preparing, filing, prosecuting and
maintaining the LICENSED SUBJECT MATER would, notwithstanding Article XI, be limited to a percentage of such costs based on the number of licenses of such LICENSED SUBJECT MATTER. For example, if there were four licenses, the percentage [***]%. 

IV. CONSIDERATION, PAYMENTS AND REPORTS 

4.1 In consideration of rights granted by BOARD to LICENSEE under this AGREEMENT, LICENSEE agrees to pay UTMDACC the following: 

(a) All out-of-pocket expenses incurred as of the EFFECTIVE DATE by UTMDACC in filing, prosecuting, enforcing and maintaining PATENT RIGHTS,
and all such future expenses incurred by UTMDACC, for so long as, and in such countries as this AGREEMENT remains in effect. UTMDACC will invoice LICENSEE after the AGREEMENT has been fully executed by all parties for expenses incurred as of that
time and on a quarterly basis thereafter. The invoiced amounts will be due and payable by LICENSEE within thirty (30) calendar days of invoice; and 

(b) A nonrefundable license documentation fee in the amount of $ . This fee will not reduce the amount of any other payment provided for in
this ARTICLE IV, and is due and payable within thirty (30) calendar days after the AGREEMENT has been fully executed by all parties and LICENSEE has received an invoice for the amount from UTMDACC; and 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 7 

 (c) Nonrefundable annual maintenance fees due and payable as follows until the first SALE: 

 

	 	•	 	First, second, third and fourth anniversary of the EFFECTIVE DATE: $            ;Fifth and all subsequent anniversaries of the EFFECTIVE DATE until first SALE:
$            ; (collectively, the “Annual Maintenance Fee”). 

The Annual Maintenance Fees will be due without invoice within thirty (30) days of each anniversary of the EFFECTIVE DATE until first
SALE and will not reduce the amount of any other payment provided for in this ARTICLE IV; and 
 (d) A running royalty equal to
            percent (    %) of NET SALES attributed to SALES of LICENSED PRODUCTS by LICENSEE, AFFILIATES and SUBLICENSEES, subject to the following: 

 

	 	•	 	It is understood that royalties, shall be due under this Section 4.1(d) above only on SALES of LICENSED PRODUCTS, the SALE of which would, but for the license granted herein, infringe a VALID CLAIM in the country
for which such LICENSED PRODUCT is SOLD. However, if the SALE of a LICENSED PRODUCT would infringe a VALID CLAIM in the MAJOR MARKET COUNTRIES, LICENSEE shall pay royalties hereunder on all sales of such LICENSED PRODUCT in any country, regardless
of whether the sale of such product in such country would infringe a VALID CLAIM. 

  

	 	•	 	In the event that more than one patent within the PATENT RIGHTS is applicable to any LICENSED PRODUCT subject to royalties under this Section 4.1(d), then only one royalty shall be paid to UTMDACC in respect of
such quantity of the LICENSED PRODUCTS and in any event no more than one royalty will be payable hereunder with respect to any particular LICENSED PRODUCT unit; 

  
 8 

	 	•	 	No royalty shall be payable under this Section 4.1(d) with respect to the SALE of LICENSED PRODUCTS between or among LICENSEE, AFFILIATES and SUBLICENSEES, provided that such LICENSED PRODUCTS are to be resold to
unrelated third parties, or with respect to any fees or other payments paid between or among LICENSEE and AFFILIATES; nor shall a royalty be payable under this Section 4.1(d) with respect to SALES of LICENSED PRODUCTS for use in clinical trials
or as samples; 

  

	 	•	 	In the event that a LICENSED PRODUCT is sold in combination as a single product, or in a kit, with another product or component and no royalty would be due hereunder on the sale of such other product or component alone,
then NET SALES from such combination sales for purposes of calculating the amounts due under this Section 4.1(d) shall be as reasonably allocated, as determined in good faith by LICENSEE and UTMDACC, between such LICENSED PRODUCT and such other
product or components, based upon their relative importance and proprietary protection as commercially reasonable; 

  

	 	•	 	To the extent that the LICENSEE is required, by order or judgment of any court to obtain in any jurisdiction any license from a third party in order to practice the rights granted to the LICENSEE hereunder, or LICENSEE
otherwise reasonably determines that such a license is necessary, then [***] of the royalties payable to such third party may be deducted from royalties otherwise payable to UTMDACC from the LICENSEE in that jurisdiction, provided that in no event
shall the royalties payable to UTMDACC pursuant to this Section 4.1(d) in any quarterly period in such jurisdiction be reduced by [***] as a result of any such deduction; and 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 9 

	 	•	 	Notwithstanding the foregoing, if SALES of a LICENSED PRODUCT subject to royalty obligations under this Section 4.1(d) are also subject to a royalty under one or more other agreements entered into by Introgen
Therapeutics, Inc. and UTMDACC, LICENSEE may reduce the royalties payable hereunder with respect to SALES of such LICENSED PRODUCT in direct proportion to the number of such other agreements. For example, if in addition to royalty obligations under
Section 4.1(d) of this Agreement, SALES of LICENSED PRODUCTS will be subject to royalties under one such additional agreement, LICENSEE may reduce the royalties payable hereunder by fifty percent (50%); if in addition to royalty obligations
under Section 4.1(d) of this Agreement, SALES of LICENSED PRODUCTS will be subject to royalties under two such additional agreements, LICENSEE may reduce the royalties [***]; if in addition to royalty obligations under Section 4.1(d) of
this Agreement, SALES of LICENSED PRODUCTS will be subject to royalties under three such additional agreements, [***]; etc. (such percentage reductions, the “PROPORTIONAL PERCENTAGE REDUCTIONS”). To the extent such other agreements do not
provide for a corresponding PROPORTIONAL PERCENTAGE REDUCTION in the royalties payable thereunder to account for royalties payable under this AGREEMENT, they shall by this AGREEMENT be deemed amended to provide for such corresponding PROPORTIONAL
PERCENTAGE REDUCTION in the royalties payable thereunder; and 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 10 

 (e) After first SALE, minimum annual royalties of
$            . This amount shall be due and payable within thirty (30) days of the first and all subsequent anniversaries of the EFFECTIVE DATE which follows the first SALE
(“Minimum Annual Royalties”); provided, however, that in the event that there is less than a twelve month period between the first SALE and the first anniversary of the EFFECTIVE DATE which follows the first SALE, then LICENSEE shall pay
the following: (1) the Annual Maintenance Fee due for that year multiplied buy the fraction, A/C, where A is the number of months between the anniversary of the EFFECTIVE DATE preceding the first SALE and the first SALE and C is twelve (12);
and (2) the Minimum Annual Royalty multiplied by the fraction B/C, where B is the number of months between the first SALE and the first anniversary of the EFFECTIVE DATE which follows the first SALE, C is twelve and A + B = twelve (12).
Additionally, running royalties accrued under Section 4.1(d) and paid to UTMDACC during the one year period preceding an anniversary of the EFFECTIVE DATE shall be credited against the Minimum Annual Royalties due on that anniversary date; and

 (f) the following percentage of SUBLICENSE INCOME received by LICENSEE: 

 

	 	•	 	            percent (    %) of SUBLICENSE INCOME received by the LICENSEE from the EFFECTIVE DATE until the first anniversary thereof; and

  

	 	•	 	            percent (    %) of SUBLICENSEE INCOME received by LICENSEE on and after the first anniversary of the EFFECTIVE DATE until the
termination or expiration of this AGREEMENT. Additionally, the maximum payment to UTMDACC under Section 4.1(f) for each sublicense agreement is $            . 

  
 11 

 4.2 Unless otherwise provided, all such payments are payable within thirty (30) calendar
days after March 31, June 30, September 30, and December 31 of each year during the term of this AGREEMENT, at which time LICENSEE will also deliver to UTMDACC a true and accurate report, giving such particulars of the business
conducted by LICENSEE, its AFFILIATES and its SUBLICENSEES, if any exist, during the preceding three (3) calendar months under this AGREEMENT as necessary for UTMDACC to account for LICENSEE’s payments hereunder. This report will include
pertinent data, including, but not limited to: 
 (a) the accounting methodologies used to account for and calculate the items included in
the report and any differences in such accounting methodologies used by LICENSEE since the previous report; and 
 (b) a list of LICENSED
PRODUCTS produced for the three (3) preceding calendar month’s; and 
 (c) the total quantities of LICENSED PRODUCTS produced; and

 (d) the total SALES; and 

(e) the calculation of NET SALES; and 

(f) the royalties so computed and due UTMDACC) and/or minimum royalties; and 

(g) all SUBLICENSING INCOME received from each SUBLICENSEE and payments due UTMDACC under Section 4.1(f); and 

(h) all other amounts due UTMDACC herein. 

Simultaneously with the delivery of each such report, LICENSEE agrees to pay UTMDACC the amount due, if any, for the period of such report. These reports are
required even if no payments are due. 

  
 12 

 4.3 During the term of this AGREEMENT and for one (1) year thereafter, LICENSEE agrees to
keep complete and accurate records of its, its AFFILIATES’ and its SUBLICENSEES’ SALES and NET SALES in sufficient detail to enable the royalties and, other payments due hereunder to be determined. LICENSEE agrees to permit UTMDACC or its
representatives, at UTMDACC’s expense, to periodically examine LICENSEE’s books, ledgers, and records during regular business hours for the purpose of and to the extent necessary to verify any report required under this AGREEMENT. If any
amounts due UTMDACC are determined to have been underpaid in an amount equal to or greater than [***] of the total amount due during the period so examined, then LICENSEE will pay the cost of the examination plus accrued interest at the highest
allowable rate. 
 4.4 Within thirty (30) calendar days following each anniversary of the EFFECTIVE DATE, LICENSEE will deliver to
UTMDACC a written progress report as to LICENSEE’s (and any SUBLICENSEE’s) efforts and accomplishments during the preceding year in diligently commercializing LICENSED SUBJECT MATTER in the LICENSED TERRITORY and LICENSEE’s (and
SUBLICENSEE’s) commercialization plans for the upcoming year. 
 4.5 All amounts payable hereunder by LICENSEE will be paid in United
States funds without deductions for taxes, assessments, fees, or charges of any kind. Checks are to be made payable to The University of Texas M. D. Anderson Cancer Center, and sent by United States mail to Box 297402, Houston, Texas 77297,
Attention: Grants and Contracts or by wire transfer to: 
 JPMorgan Chase Bank, N.A. 

910 Travis 
 Houston, Texas 77002 

 

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 13 

 SWIFT: CHASUS33 (for international wires only) 

ABA ROUTING NO: 021000021 
 ACCOUNT NAME: Univ. of Texas M. D.
Anderson Cancer Center 
 ACCOUNT NO.: 1586838979 
 REFERENCE:
include title and EFFECTIVE DATE of AGREEMENT and type of payment (e.g., license documentation fee, milestone payment, royalty [including applicable patent/application identified by MDA reference number and patent number or application serial
number], or maintenance fee, etc.). 
 4.6 No payments due or royalty rates owed under this AGREEMENT will be reduced as the result of
co-ownership of LICENSED SUBJECT MATER by BOARD and LICENSEE. 
 V. SPONSORED RESEARCH 

5.1 If LICENSEE desires to sponsor research for or related to the LICENSED SUBJECT MATER, and particularly where LICENSEE receives payments
for sponsored research pursuant to a sublicense under this AGREEMENT, LICENSEE (a) will notify UTMDACC in writing of all opportunities to conduct this sponsored research (including clinical trials, if applicable), (b) will solicit research
and/or clinical proposals from UTMDACC for this purpose, and (c) will give god faith consideration to funding the proposals at UTMDACC. 

VI. PATENTS AND INVENTIONS 

6.1 If after consultation with LICENSEE both parties agree that a new patent application should be filed for LICENSED SUBJECT MATER, UTMDACC
will prepare and file appropriate patent applications, and LICENSEE will pay the cost of searching, preparing, filing, prosecuting and maintaining same. If LICENSEE notifies UTMDACC that it does not intend to pay the cost of an application, or if
LICENSEE does not respond or make an effort to agree with UTMDACC on the disposition of rights of the subject invention, then UTMDACC may file such application at its own expense and LICENSEE’s rights to such application under this AGREEMENT
shall terminate in their entirety; provided, however, that if LICENSEE files and maintains patents in the MAJOR 

  
 14 

 
MARKET COUNTRIES, UTMDACC may not terminate LICENSEE’s rights to applications filed in other jurisdictions. UTMDACC will provide LICENSEE with a copy of the application for which LICENSEE
has paid the cost of filing, as well as copies of any documents received or filed during prosecution thereof. UTMDACC shall consult with LICENSEE in a timely manner concerning (i) scope and content of all patent applications within the PATENT
RIGHTS prior to filing such patent applications, and (ii) content of and proposed responses to official actions of the United States Patent and Trademark Office and foreign patent offices during prosecution of any patent applications within the
PATENT RIGHTS. For purposes of this Paragraph 6.1, “timely” shall mean sufficiently in advance of any decision by UTMDACC or any deadline imposed upon written response by UTMDACC so as to allow LICENSEE to meaningfully review such decision
or written response and also provide comments to UTMDACC in advance of such decision or deadline to allow comments of LICENSEE respect to the PATENT RIGHTS to be considered and incorporated into UTMDACC’s decision or written response. The
parties agree that they share a common legal interest to get valid enforceable patents and that LICENSEE will keep all privileged information received pursuant to this Section confidential. 

6.2 With respect to the filing of any patent application within the PATENT RIGHTS, or the prosecution of any patent application within the
PATENT RIGHTS, or the maintenance of any patent within the PATENT RIGHTS, if UTMDACC elects not to file for or continue prosecution of any such patent application or maintain any such patent, UTMDACC shall promptly notify LICENSEE in writing
sufficiently in advance of any deadline to enable LICENSEE to file for or continue prosecution of such patent application and/or maintain such patent, and in such event LICENSEE (or its designee) may at its discretion pursue such filing, prosecution
and/or maintenance of its own expense in UTMDACC’s name. 

  
 15 

 VII. INFRINGEMENT BY THIRD PARTIES 

7.1 LICENSEE, at its expense, shall use commercially reasonable efforts to enforce any patent exclusively licensed hereunder against
substantial and continuing infringement by third parties and is entitled to retain recovery from such enforcement. It is understood, however, that such obligation shall not be deemed to require LICENSEE to take such actions with respect to each such
infringement, and LICENSEE may take into account reasonable strategic and other considerations in determining which infringers to take action against, as well as when and whether to do so. After reimbursement of LICENSEE’s reasonable legal
costs and expenses related to such recovery, LICENSEE agrees to pay a percentage of the monetary recovery it receives to UTMDACC, such percentage to be equal to the percentage that would apply under Section 4.1 if such monetary recovery was
considered SUBLICENSE INCOME under this AGREEMENT; provided that for any monetary recovery that is for sales of LICENSED PRODUCTS lost to the infringement, in no event shall LICENSEE be responsible to pay UTMDACC amounts in excess of the royalty
detailed in Section 4.1(d) for such lost sales. LICENSEE must notify UTMDACC in writing of any material potential infringement within thirty (30) calendar days of knowledge thereof. If within twelve (12) months of a request by UTMDACC
to file suit, LICENSEE does not file suit against a third party that UTMDACC and LICENSEE mutually agree is a substantial infringer and that enforcement would be in the best interest of the licensed products (such agreement not to be unreasonably
withheld), or where there is a good-faith dispute on the matter, it is so determined pursuant to the dispute-resolution procedures of Section 15.6 below, then BOARD or UTMDACC may, at its sole discretion, enforce any patent licensed hereunder
against the infringing activities of such infringer, 

  
 16 

 
with UTMDACC retaining [***] all recoveries from such enforcement after reimbursement of UTMDACC’s reasonable legal costs and expenses related to such recovery; provided LICENSEE shall
always have the option to jointly participate in such enforcement action, including, at LICENSEE’s discretion, by jointly bringing the action with UTMDACC or joining as a party plaintiff. If LICENSEE joins such suit and shares in the legal
costs and expenses of the enforcement, then any recovery from such enforcement shall be shared by the parties in direct proportion to the reasonable legal costs and expenses paid by each party related to the recovery; provided that in no event shall
UTMDACC retain more than [***] of any recovery after reimbursement of the parties’ legal costs. 
 7.2 In any suit or dispute involving
an infringer, the parties agree to cooperate fully with each other. At the request and expense of the party bringing suit, the other party will permit reasonable access during regular business hours, to all relevant personnel, records, papers,
information, samples, specimens, and the like in its possession, and where LICENSEE is the party bringing the suit, BOARD and UTMDACC will, subject to the statutory authority of the Attorney General of the State of Texas, join the suit as a party
plaintiff and sign all documents necessary to do so. 
 VIII. PATENT MARKING 

8.1 LICENSEE agrees that all packaging containing individual LICENSED PRODUCT(S), documentation therefor, and, when possible, actual LICENSED
PRODUCT(S) sold by LICENSEE, AFFILIATES, and/or SUBLICENSEES of LICENSEE will be permanently and legibly marked with the number of any applicable patent(s) licensed hereunder in accordance with each country’s patent laws, including
Title 35, United States Code. 
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 17 

 IX. INDEMNIFICATION AND INSURANCE 

9.1 LICENSEE agrees to hold harmless and indemnify BOARD, SYSTEM, UTMDACC, their Regents, officers, employees, students and agents from and
against any claims, demands, or causes of action whatsoever, costs of suit and reasonable attorney’s fees, including without limitation, those costs arising on account of any injury or death of persons or damage to property caused by, or
arising out of, or resulting from, the exercise or practice of the rights granted hereunder by LICENSEE, its officers, its AFFILIATES or their officers, employees, agents or representatives. 

9.2 In no event shall BOARD, SYSTEM or UTMDACC be liable for any indirect, special, consequential or punitive damages (including, without
limitation, damages for loss of profits or expected savings or other economic losses, or for injury to persons or property) arising out of, or in connection with, this AGREEMENT or its subject matter, regardless of whether BOARD, SYSTEM or UTMDACC
knows or should know of the possibility of such damages. 
 9.3 Beginning at the time when any LICENSED SUBJECT MATTER is being distributed
or sold (including for the purpose of obtaining regulatory approvals) by LICENSEE, an AFFILIATE, or by a SUBLICENSEE, LICENSEE shall, at its sole cost and expense, procure and maintain commercial general liability insurance in amounts not less than
$2,000,000 per incident and $2,000,000 annual aggregate, and LICENSEE shall use reasonable efforts to have the BOARD, SYSTEM, UTMDACC, their Regents, officers, employees, students and agents named as additional insureds. Such commercial general
liability insurance shall provide: (i) product liability coverage; (ii) broad form contractual liability coverage for LICENSEE’s indemnification under this AGREEMENT; and (iii) coverage for litigation costs. The minimum amounts
of insurance coverage required herein shall not be construed to create a limit of LICENSEE’s liability with respect to its indemnification under this AGREEMENT. 

  
 18 

 9.4 LICENSEE shall provide UTMDACC with written evidence of such insurance within thirty
(30) calendar days of its procurement. Additionally, LICENSEE shall provide UTMDACC with written notice of at least fifteen (15) calendar days prior to the cancellation, non-renewal or material change in such insurance. 

9.5 LICENSEE shall maintain such commercial general liability insurance beyond the expiration or termination of this AGREEMENT during:
(i) the period that any LICENSED PRODUCTS developed pursuant to this AGREEMENT are being commercially distributed or sold by LICENSEE, an AFFILIATE or by a SUBLICENSEE of LICENSEE; and (ii) the five (5) year period immediately after
such period. 
 X. USE OF BOARD AND UTMDACC’S NAME 

10.1 LICENSEE will not use the name of (or the name of any employee of) UTMDACC, SYSTEM or BOARD in any advertising, promotional or sales
literature, on its Web site, or for the purpose of raising capital without the advance express written consent of BOARD secured through: 

The University of Texas 
 M. D.
Anderson Cancer Center 
 Legal Services, Unit 0537 

P.O. Box 301439 
 Houston, TX
77230-1439 
 ATTENTION: Natalie Wright 

Email: nwright@mdanderson.org 

Notwithstanding the above, LICENSEE may use the name of (or name of employee of) UTMDACC, SYSTEM or BOARD in routine business correspondence, or as needed in
appropriate regulatory submissions without express written consent, including when indicating, as a factual matter, that 

  
 19 

 
UTMDACC, SYSTEM or BOARD is a licensor of LICENSEE under this AGREEMENT in connection with either or both of the following: 

(a) communications associated with LICENSEE’S financing activities; and 

(b) communications (other than promotions and advertisements) directed to describing or responding to inquiries concerning the business,
technology, products, services and associated activities of LICENSEE. 
 XI. CONFIDENTIAL INFORMATION AND PUBLICATION 

11.1 UTMDACC and LICENSEE each agree that all information contained in documents marked “confidential” and forwarded to one by the
other (i) are to be received in strict confidence, (ii) are to be used only for the purposes of this AGREEMENT, and (iii) will not be disclosed by the recipient party (except as required by law or court order), its agents or employees
without the prior written consent of the disclosing party, except to the extent that such information: 
 (a) was in the public domain at
the time of disclosure; or 
 (b) later became part of the public domain through no act or omission of the recipient party, its employees,
agents, successors or assigns; or 
 (c) was lawfully disclosed to the recipient party by a third party having the right to disclose it; or

 (d) was already known by the recipient party at the time of disclosure, as demonstrated by competent written proof (such as
contemporaneous records); or 
 (e) was independently developed by the recipient party without use of the disclosing party’s
confidential information, as demonstrated by competent written proof (such as contemporaneous records); or 
 (f) is required by law or
regulation to be disclosed. 

  
 20 

 Notwithstanding the foregoing, LICENSEE may disclose any LICENSED SUBJECT MATTER comprising the confidential
information of UTMDACC to third parties pursuant to a commercially reasonable confidentiality agreement, or otherwise in connection with the exercise of its license rights under this AGREEMENT. 

11.2 Each party’s obligation of confidence hereunder will be fulfilled by using at least the same degree of care with the disclosing
party’s confidential information as it uses to protect its own confidential information, but always at least a reasonable degree of care. This obligation will exist while this AGREEMENT is in force and for a period of three (3) years
thereafter. 
 11.3 UTMDACC reserves the right to publish the general scientific findings from research related to LICENSED SUBJECT MATTER,
with due regard to the protection of LICENSEE’s confidential information. UTMDACC will submit the manuscript of any proposed publication to LICENSEE at least thirty (30) calendar days before publication, and LICENSEE shall have the right
to review and comment upon the publication in order to protect LICENSEE’s confidential information. Upon LICENSEE’s request, publication may be delayed up to sixty (60) additional calendar days to enable LICENSEE to secure adequate
intellectual property protection of LICENSEE’s confidential information that would otherwise be affected by the publication. 
 XII.
ASSIGNMENT 
 12.1 Except in connection with the sale of all or substantially all of LICENSEE’s business or assets relating to this
AGREEMENT to a third party, this AGREEMENT may not be assigned by LICENSEE without the prior written consent of UTMDACC, which will not be unreasonably withheld. 

  
 21 

 XIII. TERM AND TERMINATION 

13.1 Subject to Sections 13.3 and 13.4 hereinbelow, the term of this AGREEMENT is from the EFFECTIVE DATE to the full end of the term or
terms for which PATENT RIGHTS have not expired, been revoked or invalidated, provided that LICENSEE’s license with respect to the TECHNOLOGY RIGHTS shall survive the expiration of this AGREEMENT and be considered fully-paid up. 

13.2 Any time after three (3) years from the EFFECTIVE DATE, BOARD or UTMDACC have the right to terminate the exclusivity of this license
in any national political jurisdiction within the LICENSED TERRITORY if LICENSEE, within ninety (90) calendar days after receiving written notice from UTMDACC of the intended termination, fails to provide reasonable written evidence that
LICENSEE or its SUBLICENSEE(s) has commercialized or is actively and effectively attempting to commercialize a licensed invention in such jurisdiction(s), provided that if LICENSEE or its SUBLICENSEE(s) has commercialized or is actively and
effectively attempting to commercialize a licensed invention within any of the United States, Japan or any MAJOR MARKET COUNTRY in Europe, LICENSEE shall be considered to have satisfied its obligations under this Section 13.2 worldwide. The
following definitions apply to Section 13.2: (a) “commercialized” means having SALES in such jurisdiction; and(b) “actively and effectively attempting to commercialize” means having an ongoing and active research,
development, manufacturing, marketing or sales program as appropriate, directed toward developing, obtaining regulatory approval, and/or production and/or SALES in any jurisdiction. 

  
 22 

 13.3 Subject to any rights herein which survive termination, this AGREEMENT will earlier
terminate in its entirety: 
 (a) automatically, if LICENSEE becomes bankrupt and/or if the business of LICENSEE shall be placed in the
hands of a receiver, assignee, or trustee, whether by voluntary act of LICENSEE or otherwise; or 
 (b) upon thirty (30) calendar days
written notice from UTMDACC, if LICENSEE breaches or defaults on the payment or report obligations of ARTICLE IV, or use calendar day notice period, LICENSEE has cured the default or breach, and so notifies UTMDACC, stating the manner of the cure;
or 
 (c) upon ninety (90) calendar days written notice from UTMDACC if LICENSEE breaches or defaults on any other material obligation
under this AGREEMENT, unless, before the end of the such ninety (90) calendar-day notice period, LICENSEE has cured the default or breach and so notifies UTMDACC, stating the manner of the cure; or 

(d) at any time by mutual written agreement between LICENSEE and UTMDACC upon one hundred eighty (180) calendar days written notice to
all parties and subject to any terms herein which survive termination; or 
 (e) upon thirty (30) calendar days written notice from
LICENSEE to UTMDACC of LICENSEE’S intent to terminate, which notice LICENSEE may provide (i) for any reason or no reason, and (ii) with respect to the AGREEMENT in its entirety or with respect to any family of patents or patent
applications within the PATENT RIGHTS that correspond to an individual MDA case number. 
 Notwithstanding the foregoing, if before the end
of the applicable cure period of Section 13.3(b) or (c) above, LICENSEE disputes the breach or default claimed by UTMDACC, UTMDACC shall not have the right to terminate this AGREEMENT unless and until the parties have completed the dispute
resolution procedure outlines in Section 15.6, LICENSEE is found to 

  
 23 

 
have materially breached this AGREEMENT, and LICENSEE fails to cure such breach within the applicable cure period following such determination; provided that the foregoing shall not suspend any
obligation of LICENSEE to pay to UTMDACC any undisputed amount owed by LICENSEE to UTMDACC under this AGREEMENT, during the pendency of any determination of breach. Additionally, UTMDACC can terminate according to Section 13.3(b) above if it is
for nonpayment of patent expenses pursuant to Section 4.1(a), nonpayment of the license documentation fee in Section 4.1(b), nonpayment of the Annual Maintenance Fees in Section 4.1(c) or nonpayment of the Minimum Annual Royalties in
Section 4.1(e). 
 13.4 Upon termination of this AGREEMENT: 

(a) nothing herein will be construed to release either party of any obligation maturing prior to the effective date of the termination; and

 (b) the parties covenant and agree to be bound by the provisions of Articles IX (Indemnification and Insurance), X (Use of Board and
UTMDACC’s Name) and XI (Confidential Information and Publication) of this AGREEMENT, and any other provisions that by their nature or as otherwise provided herein, are intended to survive this AGREEMENT; and 

(c) LICENSEE may, for a period of one year after the effective date of the termination, sell all LICENSED PRODUCTS and parts therefor that it
has on hand at the date of termination, if LICENSEE pays the earned royalty thereon and any other amounts due pursuant to Article IV of this AGREEMENT; and 

(d) Subject to Sections, 3.5, 13.1 and 13.4(c), the license granted to LICENSEE under Section 3.1 shall terminate and LICENSEE agrees to
cease and desist any use and all SALE of the LICENSED SUBJECT MATTER and LICENSED PRODUCTS upon termination of this AGREEMENT. 

  
 24 

 
XIV. WARRANTY: SUPERIOR-RIGHTS 
 14.1 Except for the rights, if any, of the
Government of the United States of America as set forth below, BOARD represents and warrants its belief that (a) it is the owner of the entire right, title, and interest in and to LICENSED SUBJECT MATTER, (b) it has the sole right to grant
licenses thereunder, and (c) it has not knowingly granted licenses thereunder to any other entity that would restrict rights granted hereunder except as stated herein. 

14.2 LICENSEE understands that the LICENSED SUBJECT MATTER may have been developed under a funding agreement with the Government of the United
States of America (“Government”) and, if so, that the Government may have certain rights relative thereto. This AGREEMENT is explicitly made subject to the Government’s rights under any such agreement and any applicable law or
regulation. To the extent that there is a conflict between any such agreement, applicable law or regulation and this AGREEMENT, the terms of such Government agreement, applicable law or regulation shall prevail. To the extent required by applicable
law or regulation, LICENSEE agrees that LICENSED PRODUCTS used or SOLD in the United States will be manufactured substantially in the United States, unless a written waiver is obtained in advance from the GOVERNMENT. LICENSEE will promptly advise
UTMDACC if such a written waiver is requested and/or obtained. 
 14.3 LICENSEE understands and agrees that BOARD and UTMDACC, by this
AGREEMENT, make no representation as to the operability or fitness for any use, safety, efficacy, approvability by regulatory authorities, time and cost of development, patentability, and/or breadth of the LICENSED SUBJECT MATTER. BOARD and UTMDACC,
by this AGREEMENT, also make no representation as to whether any patent covered by PATENT RIGHTS is valid or as to whether there are any patents now held, or which will be held, by others or by BOARD or

  
 25 

 
UTMDACC in the LICENSED FIELD, nor do BOARD and UTMDACC make any representation that the inventions contained in PATENT RIGHTS do not infringe any other patents now held or that will be held by
others or by BOARD. 
 14.4 LICENSEE, by execution hereof, acknowledges, covenants and agrees that LICENSEE has not been induced in any way
by BOARD, SYSTEM, UTMDACC or employees thereof to enter into this AGREEMENT and LICENSEE is entering into this AGREEMENT voluntarily. 

XV. GENERAL 
 15.1 This
AGREEMENT constitutes the entire and only agreement between the, parties for LICENSED SUBJECT MATTER and all other prior .negotiations, representations, agreements and understandings are superseded hereby. No agreements altering or supplementing the
terms hereof will be made except by a written document signed by both parties. 
 15.2 Any notice required by this AGREEMENT must be given
by prepaid, first class, certified mail, return receipt requested, and addressed in the case of UTMDACC to: 
 The University of Texas M. D.
Anderson Cancer Center 
 Office of Technology Commercialization 

7515 S. Main, Suite 490, Unit 0510 

Houston, Texas 77030 
 ATTENTION:
Christopher C. Capelli, M.D. 
 or in the case of LICENSEE to: 

Introgen Therapeutics, Inc. 
 301
Congress, Suite 1850 
 Austin, Texas 78701 

ATTENTION: David Nance 
 or other addresses as
may be given from time to time under the terms of this notice provision. 

  
 26 

 15.3 LICENSEE must comply with all applicable federal, state and local laws and regulations in
connection with its activities pursuant to this AGREEMENT. 
 15.4 LICENSEE acknowledges that the LICENSED SUBJECT MATTER is subject to U.
S. export control jurisdiction. LICENSEE agrees to comply with all applicable international and national laws that apply to the LICENSED SUBJECT MATTER, including U.S. Export Administration Regulations, as well as end-user, end-use, and destination
restrictions applied by the United States. 
 15.5 This AGREEMENT will be construed and enforced in accordance with the laws of the United
States of America and of the State of Texas, without regard to its conflict of law provisions. The Texas State Courts of Harris County, Texas (or, if there is exclusive federal jurisdiction, -the United States District Court for the Southern
District of Texas) shall have exclusive jurisdiction and venue over any dispute arising out of this AGREEMENT, and LICENSEE consents to the jurisdiction of such courts; however, nothing in this AGREEMENT shall be deemed as a waiver by BOARD, SYSTEM
or UTMDACC of its sovereign immunity. 
 15.6 Certain disputes arising out of or relating to this AGREEMENT, its construction or its actual
or alleged breach may be decided by mediation. If the mediation does not result in a resolution of such dispute or controversy, it will be finally decided by binding arbitration, conducted in the city of Houston, Harris County, Texas, in accordance
with the applicable, then-current procedures of the American Arbitration Association. The arbitration panel will include members knowledgeable in the evaluation of the LICENSED SUBJECT MATTER. Judgment upon the award rendered may be entered in the
highest court or forum having jurisdiction, state or federal. The provisions of this Section 15.6 will not apply to decisions on the validity of patent claims or to any dispute or controversy as to which any treaty or law prohibits such
arbitration. Notwithstanding the foregoing, the decision of the arbitration must be sanctioned by a court of law having jurisdiction to be binding upon and enforceable by the parties. 

  
 27 

 15.7 Failure of BOARD or UTMDACC to enforce a right under this AGREEMENT will not act as a waiver
of right or the ability to later assert that right relative to the particular situation involved. 
 15.8 Headings included herein are for
convenience only and will not be used to construe this AGREEMENT. 
 15.9 If any part of this AGREEMENT is for any reason found to be
unenforceable, all other parts nevertheless will remain enforceable. 
 15.10 In the event that LICENSEE brings an action before any court,
agency or tribunal seeking to invalidate or otherwise challenge the enforceability of or BOARD’s ownership of any patent included in the PATENT RIGHTS, then UTMDACC may immediately terminate this AGREEMENT upon written notice to LICENSEE.
Additionally, LICENSEE will provide written notice to UTMDACC at least three (3) months prior to seeking to invalidate or challenge any patent under the PATENT RIGHTS. LICENSEE will include with such written notice an identification of all
prior art it believes invalidates any claim of a patent under the PATENT RIGHTS and will promptly update such disclosure as LICENSEE becomes aware of additional prior art. Any dispute regarding the validity, enforceability or ownership of any patent
included in the PATENT RIGHTS shall be litigated in the courts located in Houston, Texas, and LICENSEE agrees not to challenge personal jurisdiction in that forum. To the extent that LICENSEE unsuccessfully challenges the validity or enforceability
of any patent included in the PATENT RIGHTS, LICENSEE agrees to reimburse UTMDACC and BOARD for all costs and fees (including attorney’s fees) paid by UTMDACC and BOARD in defending against such challenge. LICENSEE understands and agrees

  
 28 

 
that, in the event LICENSEE successfully challenges the validity or enforceability of any patent included in the PATENT RIGHTS, all payments or other consideration made or otherwise provided by
LICENSEE to UTMDACC prior to a final, non-appealable adjudication of invalidity and/or unenforceability shall be non-refundable. The obligations of this Section shall survive the expiration or termination of this AGREEMENT. 

  
 29 

 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives
to execute this AGREEMENT. 
  

									
	BOARD OF REGENTS OF THE
UNIVERSITY OF TEXAS SYSTEM	 		 	INTROGEN THERAPEUTICS, INC.
					
	By	 	  
	 		 	By	 	  

		 	John Mendelsohn, M.D.	 		 	Name:	 	  

		 	President	 		 	Title:	 	  

		 	The University of Texas	 		 		 	
		 	M. D. Anderson Cancer Center	 		 		 	
					
	Date:	 	  
	 		 	Date:	 	  

				
	THE UNIVERSITY OF TEXAS
M. D. ANDERSON CANCER CENTER	 		 		 	
					
	By	 	  
	 		 		 	
		 	Leon Leach	 		 		 	
		 	Executive Vice President	 		 		 	
		 	The University of Texas	 		 		 	
		 	M. D. Anderson Cancer Center	 		 		 	
					
	Date:	 	  
	 		 		 	
				
	Approved as to Content:	 		 		 	
					
	By	 	  
	 		 		 	
		 	Christopher C. Capelli	 		 		 	
		 	Vice President, Technology Transfer	 		 		 	
		 	M. D. Anderson Cancer Center	 		 		 	
					
	Date:	 	  
	 		 		 	

  
 30 

 EXHIBIT I 
  

  
 31 

 Attachment B-2 

Form of Non-Exclusive License Agreement 
  

  
 1 

 NON-EXCLUSIVE PATENT AND TECHNOLOGY LICENSE AGREEMENT 

This             
(            ) page AGREEMENT (“AGREEMENT”) is made on this      day of
                    , 200  , by and between THE BOARD OF REGENTS (“BOARD”) of THE UNIVERSITY OF TEXAS SYSTEM
(“SYSTEM”), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (“UTMDACC”), a component institution of SYSTEM, and
Introgen Therapeutics, Inc., a Texas corporation having a principal place of business located at 301 Congress, Suite 1850, Austin, Texas 78701 (“LICENSEE”). 

RECITALS 
 A. BOARD owns
certain PATENT RIGHTS ‘and TECHNOLOGY RIGHTS related to LICENSED SUBJECT MATTER developed at UTMDACC. 
 B. BOARD, through UTMDACC,
desires to have the LICENSED SUBJECT MATTER developed in the LICENSED FIELD and used for the benefit of LICENSEE, BOARD, SYSTEM, UTMDACC, the inventor(s), and the public as outlined in BOARD’s Intellectual Property Policy. 

C. LICENSEE wishes to obtain a license from BOARD to practice LICENSED SUBJECT MATTER. 

NOW, THEREFORE, in consideration of the mutual covenants and promises herein contained, the parties agree as follows: 

I. EFFECTIVE DATE 
 1.1
This AGREEMENT is effective as of the date of final execution of this AGREEMENT (“EFFECTIVE DATE”). 

  
 1 

 II. DEFINITIONS 

As used in this AGREEMENT, the following terms have the meanings indicated: 

2.1 AFFILIATE means any business entity more than fifty percent (50%) owned by LICENSEE, any business entity which owns more than
fifty percent (50%) of LICENSEE, or any business entity that is more than fifty percent (50%) owned by a business entity that owns more than fifty percent (50%) of LICENSEE. 

2.2 LICENSED FIELD means all fields of use. 

2.3 LICENSED PRODUCTS means any product or service sold by LICENSEE, its AFFILIATES or SUBLICENSEES comprising LICENSED SUBJECT MATTER
pursuant to this AGREEMENT. 
 2.4 LICENSED SUBJECT MATTER means inventions and discoveries covered by PATENT RIGHTS or TECHNOLOGY
RIGHTS within LICENSED FIELD. 
 2.5 LICENSED TERRITORY means worldwide. 

2.6 MAJOR MARKET COUNTRIES means, collectively, all of the United States, Japan and at least four of the following countries in Europe:
United Kingdom, France, Germany, Spain, Italy, Sweden and Switzerland. 
 2.7 NET SALES means the gross revenues received by
LICENSEE, its AFFILIATES or SUBLICENSEES from a SALE less sales discounts actually granted, sales and/or use taxes actually paid, import and/or export duties actually paid, outbound transportation actually prepaid or allowed, and amounts actually
allowed or credited due to returns (not exceeding the original billing or invoice amount), all as recorded by LICENSEE, AFFILIATES or SUBLICENSEES in their official books and records in accordance with generally accepted accounting practices and
consistent with their published financial statements and/or regulatory filings with the United States Securities and Exchange Commission. 

  
 2 

 2.8 PATENT RIGHTS means (a) all of BOARD’s rights in and to any patents and
patent applications, whether domestic or foreign, that claim any invention, information or discovery described in any of the invention disclosures defined in Exhibit I attached hereto, including the patent application listed in Exhibit I,
and all patents, whether domestic or foreign that issue thereon; and (b) all divisionals, continuations, continuations-in-part (to the extent the claims of such continuations-in-part are entitled to claim priority to the aforesaid patents
and/or patent applications defined in clause (a)), reissues, reexaminations or extensions- of the patents and patent applications defined in clause (a), and any letters patent, domestic or foreign that issue thereon. From time to time during the
term of this AGREEMENT, upon request by either party, LICENSEE and BOARD shall promptly update Exhibit I to include all patent applications and patents that are within PATENT RIGHTS. 

2.9 SALE or SOLD means the transfer or disposition of a LICENSED PRODUCT for value (or, with respect to LICENSED PRODUCTS that
are services, the provision of such services for value on a fee-for-services basis) to a party other than LICENSEE, {or} an AFFILIATE {Add the bold sections if one or more inventors are MDs:. or a ROYALTY-FREE PRACTITIONER. As used herein,
“ROYALTY-FREE PRACTITIONER” means UTMDACC and (the “PHYSICIAN INVENTOR”), and any partner or associate who practices medicine with one or more of the PHYSICIAN INVENTOR, but with respect to such partner or associate, only for
such time as they are engaged in a bona fide medical practice with one or more of the PHYSICIAN INVENTOR.] 

  
 3 

 2.10 SUBLICENSEE means any third party to whom LICENSEE has granted a sublicense under the
LICENSED SUBJECT MATTER to make and sell LICENSED PRODUCTS, with respect to LICENSED PRODUCTS made and sold by such SUBLICENSEE. As used herein, “SUBLICENSEE” shall also mean a third party to whom LICENSEE has granted the exclusive right
to distribute LICENSED PRODUCTS supplied by LICENSEE, provided that such third party is responsible for all marketing and promotion of the subject LICENSED PRODUCTS within its exclusive territory. 

2.11 SUBLICENSE INCOME means all consideration received by LICENSEE from a SUBLICENSEE in consideration of a sublicense of the LICENSED
SUBJECT MATTER, including but not limited to, up-front payments, marketing, distribution, franchise, option, license, or documentation fees, bonus and milestone payments and equity securities. SUBLICENSE INCOME shall specifically exclude:
(i) payments received by LICENSEE from a sublicense as a result of the purchase or sale of debt or equity securities of LICENSEE by such sublicense, and (ii) payments for research and development of the LICENSED PRODUCTS; and
(iii) any royalties that LICENSEE receives for the SUBLICENSEE’s sale of LICENSED PRODUCTS (which are captured under Section 4.1(c)). 

2.12 TECHNOLOGY RIGHTS means BOARD’s rights in any technical information, know-how, processes, procedures, compositions, devices,
methods, formulae, protocols, techniques, software, designs, drawings or , data created by the inventor(s) listed in Exhibit I, or those working in the lab or under the supervision or direction of one or more of the inventor(s) listed in
Exhibit I, at UTMDACC before the EFFECTIVE DATE, whether or not claimed in PATENT RIGHTS but that are reasonably necessary for practicing an invention at any time claimed in the PATENT RIGHTS. 

  
 4 

 2.13 VALID CLAIM means either (a) a claim of an issued and unexpired patent included
within the PATENT RIGHTS which has not been held unenforceable, unpatentable or invalid by the final decision of a court or other governmental agency of competent jurisdiction, in which such decision is unappealable or unappealed within the time
allowable for appeal, and which has not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a pending claim in a patent application within the PATENT RIGHTS, provided that if such pending claim has not
issued as a claim or an issued patent within the PATENT RIGHTS within five (5) years after the filing of the application in which such claim first appears, such pending claim shall not be a VALID CLAIM for purposes of this AGREEMENT, unless and
until subsequent to such five (5) year period, such pending claim is issued as a claim of an issued and unexpired patent included within the PATENT RIGHTS as set forth in (a) above. 

III. LICENSE 
 3.1 BOARD,
through UTMDACC, hereby grants to LICENSEE a royalty-bearing, non-exclusive license under LICENSED SUBJECT MATTER to manufacture, have manufactured, use, import, offer to sell and/or sell LICENSED PRODUCTS, to practice any method, process or
procedure and to otherwise exploit the LICENSED SUBJECT MATTER, in each case within LICENSED TERRITORY for use within LICENSED FIELD. This grant is subject to Sections 13.2 and 13.3 herein below and the payment by LICENSEE to UTMDACC of all
consideration as provided herein. 
 3.2 LICENSEE may extend the license granted herein to any AFFILIATE provided that the AFFILIATE
consents in writing to be bound by this AGREEMENT to the same extent as LICENSEE. LICENSEE agrees to deliver such contract to UTMDACC within thirty (30) calendar days following execution thereof. 

  
 5 

 3.3 LICENSEE may grant and authorize sublicenses under LICENSED SUBJECT MATER consistent with the
terms of this AGREEMENT. LICENSEE is responsible to use commercially reasonable efforts to cause its SUBLICENSEES to comply with the relevant obligations under this AGREEMENT, and for diligently collecting all amounts due LICENSEE from SUBLICENSEES.
If a SUBLICENSEE pursuant hereto becomes bankrupt, insolvent or is placed in the hands of a receiver or trustee, LICENSEE, to the extent allowed under applicable law and in a timely manner, agrees to use its reasonable efforts to collect all
consideration owed to LICENSEE and to have the sublicense agreement confirmed or rejected by a court of proper jurisdiction. 
 3.4 LICENSEE
must deliver to UTMDACC a true and correct copy of each sublicense granted by LICENSEE, and any modification or termination thereof, within thirty (30) calendar days after execution, modification, or termination. 

3.5 If this AGREEMENT is terminated pursuant to Article XI-Term and Termination, all sublicenses granted hereunder that are in compliance with
their terms shall survive the termination provided that each such SUBLICENSEE consents in writing to be bound directly to BOARD and UTMDACC to all of the terms and conditions of this AGREEMENT, subject to any field of use or jurisdictional
limitations provided in the original sublicense. 
 IV. CONSIDERATION, PAYMENTS AND REPORTS 

4.1 In consideration of rights granted by BOARD to LICENSEE under this AGREEMENT, LICENSEE agrees to pay UTMDACC the following: 

(a) All out-of-pocket expenses incurred as of the EFFECTIVE DATE by UTMDACC in filing, prosecuting, enforcing and maintaining PATENT RIGHTS,
and all such future expenses incurred by UTMDACC, for so long as, and in such countries as this AGREEMENT remains in effect, unless BOARD sublicenses the LICENSED SUBJECT MATTER to one or more 

  
 6 

 
third parties, in which case the expenses under this Section 4.1(a) incurred after the effective date of such third party licenses shall be pro-rated between all licensees. UTMDACC will
invoice LICENSEE after the AGREEMENT has been fully executed by all parties for expenses incurred as of that time and on a quarterly basis thereafter. The invoiced amounts will be due and payable by LICENSEE within thirty (30) calendar days of
invoice; and 
 (b) The one-time amounts set forth in the following table within thirty (30) days after the first achievement of the
corresponding milestone event (each, a “Development Milestone”) for the first LICENSED PRODUCT to meet such Development Milestone: 
  

					
	Development Milestone	  	Payment	 
	The earlier of either:	  	$	            	  
		  	  
	  
	 
	(A) First dosing of the first patient in a PHASE II CLINICAL TRIAL for a LICENSED PRODUCT in a MAJOR MARKET COUNTRY; provided that if a combined PHASE I/II CLINICAL TRIAL is conducted in lieu of separate PHASE I and PHASE II
CLINICAL TRIALS, one year after the first dosing of the first patient in the PHASE I/II CLINICAL TRIAL, or	  			
	(B) First appointment by LICENSEE of a SUBLICENSEE under the LICENSED SUBJECT MATTER to make and sell LICENSED PRODUCTS for a MAJOR MARKET COUNTRY, or for the exclusive right to ‘ distribute in a MAJOR MARKET COUNTRY LICENSED
PRODUCTS supplied by LICENSEE (provided the SUBLICENSEE is responsible for all marketing and promotion of the subject LICENSED PRODUCTS within such MAJOR MARKET COUNTRY).	  			
		  	  
	  
	 
	First MARKETING APPROVAL for a LICENSED PRODUCT in a MAJOR MARKET COUNTRY.	  	$	            	  
		  	  
	  
	 

 For purposes of this Section 4.1(b): 

 

	 	•	 	“MARKETING APPROVAL” means approval by the United States Food and Drug Administration, or the counterpart health regulatory in any other country, to market a product for general commercial sale.

  
 7 

	 	•	 	“PHASE I CLINICAL TRIAL” means a human clinical trial, the principal purpose of which is preliminary determination of safety in healthy individuals or patients as required in 21 C.F.R. § 312, or
comparable clinical trial in a country other than the United States. 

  

	 	•	 	“PHASE II CLINICAL TRIAL” means a human clinical trial, for which a primary endpoint is a preliminary determination of efficacy and/or dose ranges in patients with the disease target being studied as required
in 21 C.F.R. §312, or similar clinical study in a country other than the United States. 

  

	 	•	 	“PHASE I/II CLINICAL TRIAL” means a human clinical trial, the principal purpose of which is to             , or comparable clinical trial in a
country other than the United States. 

 (c) A running royalty equal to
            percent (    %) of NET SALES attributed to SALES of LICENSED PRODUCTS by LICENSEE, AFFILIATES and SUBLICENSEES, subject to the following: 

 

	 	•	 	It is understood that royalties shall be due under this Section 4.1(c) above only on SALES of LICENSED PRODUCTS, the SALE of which would, but for the license granted herein, infringe a VALID CLAIM in the country
for which such LICENSED PRODUCT is SOLD. However, if the SALE of a LICENSED PRODUCT would infringe a VALID CLAIM in the MAJOR MARKET COUNTRIES, LICENSEE shall pay royalties hereunder on all sales of such LICENSED PRODUCT in any country, regardless
of whether the sale of such product in such country would infringe a VALID CLAIM. 

  
 8 

	 	•	 	In the event that more than one patent within the PATENT RIGHTS is applicable to any LICENSED PRODUCT subject to royalties under this Section 4.1(c), then only one royalty shall be paid to UTMDACC in respect of
such quantity of the LICENSED PRODUCTS and in any event no more than one royalty will be payable hereunder with respect to any particular LICENSED PRODUCT unit; 

  

	 	•	 	No royalty shall be payable under this Section 4.1(c) with respect to the SALE of LICENSED PRODUCTS between or among LICENSEE, AFFILIATES and SUBLICENSEES, provided that such LICENSED PRODUCTS are to be resold to
unrelated third parties, or with respect to any fees or other payments paid between or among LICENSEE and AFFILIATES; nor shall a royalty be payable under this Section 4.1(c) with respect to SALES of LICENSED PRODUCTS for use in clinical trials
or as samples; 

  

	 	•	 	In the event that a LICENSED PRODUCT is sold in combination as a single product, or in a kit, with another product or component and no royalty would be due hereunder on the sale of such other product or component alone,
then NET SALES from such combination sales for purposes of calculating the amounts due under this Section 4.1(c) shall be as reasonably allocated, as determined in good faith by LICENSEE and UTMDACC, between such LICENSED PRODUCT and such other
product or components, based upon their relative importance and proprietary protection as commercially reasonable; 

  

	 	•	 	 To the extent that the LICENSEE is required, by order or judgment of any court to obtain in any jurisdiction any license from a third party in order
to practice the rights granted to the LICENSEE hereunder, or LICENSEE otherwise reasonably 

  
 9 

	 	 
determines that such a license is necessary, then up to fifty percent (50%) of the royalties payable to such third party may be deducted from royalties otherwise payable to UTMDACC from the
LICENSEE in that jurisdiction, provided that in 

  
 10 

	 	 
no event shall the royalties payable to UTMDACC pursuant to this Section 4.1(c) in any quarterly period in such jurisdiction be reduced by more than fifty percent (50%) as a result of
any such deduction; and 

  

	 	•	 	Notwithstanding the foregoing, if SALES of a LICENSED PRODUCT subject to royalty obligations under this Section 4.1(c) are also subject to a royalty under one or more other agreements entered into by Introgen
Therapeutics, Inc. and UTMDACC, LICENSEE may reduce the royalties payable hereunder with respect to SALES of such LICENSED PRODUCT in direct proportion to the number of such other agreements. For example, if in addition to royalty obligations under
Section 4.1(c) of this Agreement, SALES of LICENSED PRODUCTS will be subject to royalties under one such additional agreement, LICENSEE may reduce the royalties payable hereunder by fifty percent (50%); if in addition to royalty obligations
under Section 4.1(b) of this Agreement, SALES of LICENSED PRODUCTS will be subject to royalties under two such additional agreements, LICENSEE may reduce the royalties payable hereunder by [***]; if in addition to royalty obligations under
Section 4.1(c) of this Agreement, SALES of LICENSED PRODUCTS will be subject to royalties under three such additional agreements, [***]; etc. (such percentage reductions, the “PROPORTIONAL PERCENTAGE REDUCTIONS”). To the extent such
other agreements do not provide for a corresponding PROPORTIONAL PERCENTAGE REDUCTION in 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 11 

	 	 
the royalties payable thereunder to account for royalties payable under this AGREEMENT, they shall by this AGREEMENT be deemed amended to provide for such corresponding PROPORTIONAL PERCENTAGE
REDUCTION in the royalties payable thereunder; and 

 (d) the following percentage of SUBLICENSE INCOME received by
LICENSEE: 
  

	 	•	 	            percent (    %) of SUBLICENSE INCOME received by the LICENSEE from the EFFECTIVE DATE until the first anniversary thereof; and

  

	 	•	 	            percent (    %) of SUBLICENSEE INCOME received by LICENSEE on and after the first anniversary of the EFFECTIVE DATE until the
termination or expiration of this AGREEMENT. 

 Additionally, the maximum payment to UTMDACC under Section 4.1(d) for
each sublicense agreement is $            . 
 4.2 Unless otherwise provided,
all such payments are payable within thirty (30) calendar days after March 31, June 30, September 30, and December 31 of each year during the term of this AGREEMENT, at which time LICENSEE will also deliver to UTMDACC a true
and accurate report, giving such particulars of the business conducted by LICENSEE, its AFFILIATES and its SUBLICENSEES, if any exist, during the preceding three (3) calendar months under this AGREEMENT as necessary for UTMDACC to account for
LICENSEE’s payments hereunder. This report will include pertinent data, including, but not limited to: 

  
 12 

 (a) the accounting methodologies used to account for and calculate the items included in the
report and any differences in such accounting methodologies used by LICENSEE since the previous report; and 
 (b) a list of LICENSED
PRODUCTS produced for the three (3) preceding calendar months; and 
 (c) the total quantities of LICENSED PRODUCTS produced; and 

(d) the total SALES; and 
 (e)
the calculation of NET SALES; and 
 (f) the royalties so computed and due UTMDACC) and/or minimum royalties; and 

(g) all SUBLICENSING INCOME received from each SUBLICENSEE and payments due UTMDACC under 
Section 4.1(d); and 

(h) all other amounts due UTMDACC herein. 

Simultaneously with the delivery of each such report, LICENSEE agrees to pay UTMDACC the amount due, if any, for the period of such report.
These reports are required even if no payments are due. 
 4.3 During the term of this AGREEMENT and for one (1) year thereafter,
LICENSEE agrees to keep complete and accurate records of its, its AFFILIATES’ and its SUBLICENSEES’ SALES and NET SALES in sufficient detail to enable the royalties and other payments due hereunder to be determined. LICENSEE agrees to
permit UTMDACC or its representatives, at UTMDACC’s expense, to periodically examine LICENSEE’s books, ledgers, and records during regular business hours for the purpose of and to the extent necessary to verify any report required under
this AGREEMENT. If any amounts due UTMDACC are determined to have been underpaid 

  
 13 

 
in an amount equal to or greater than [***] of the total amount due during the period so examined, then LICENSEE will pay the cost of the examination plus accrued interest at the highest
allowable rate. 
 4.4 All amounts payable hereunder by LICENSEE will be paid in United States funds without deductions for taxes,
assessments, fees, or charges of any kind. Checks are to be made payable to The University of Texas M. D. Anderson Cancer Center, and sent by United States mail to Box 297402, Houston, Texas 77297, Attention: Grants and Contracts or by wire transfer
to: 
 JPMorgan Chase Bank, N.A. 

910 Travis 
 Houston, Texas 77002

 SWIFT: CHASUS33 (for international wires only) 

ABA ROUTING NO: 021000021 

ACCOUNT NAME: Univ. of Texas M. D. Anderson Cancer Center 

ACCOUNT NO.: 1586838979 

REFERENCE: include title and EFFECTIVE DATE of AGREEMENT and type of payment (e.g., license documentation fee, milestone payment, royalty
[including applicable patent/application identified by MDA reference number and patent number or application serial number], or maintenance fee, etc.). 

4.5 No payments due or royalty rates owed under this AGREEMENT will be reduced as the result of co-ownership of LICENSED SUBJECT MATTER by
BOARD and LICENSEE. 
 V. SPONSORED RESEARCH 

5.1 If LICENSEE desires to sponsor research for or related to the LICENSED SUBJECT MATTER, and particularly where LICENSEE receives payments
for sponsored research pursuant to a sublicense under this AGREEMENT, LICENSEE (a) will notify UTMDACC in writing of all opportunities to conduct this sponsored research (including clinical trials, if applicable), (b) will solicit research
and/or clinical proposals from UTMDACC for this purpose, and (c) will give good faith consideration to funding the proposals at UTMDACC. 
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 14 

 VI. PATENTS AND INVENTIONS 

6.1 If after consultation with LICENSEE both parties agree that a new patent application should be filed for LICENSED SUBJECT MATTER, UTMDACC
will prepare and file appropriate patent applications, and LICENSEE will pay the cost of searching, preparing, filing, prosecuting and maintaining same. If LICENSEE notifies UTMDACC that it does not intend to pay the cost of an application, or if
LICENSEE does not respond or make an effort to agree with UTMDACC on the disposition of rights of the subject invention, then UTMDACC may file such application at its own expense and LICENSEE’s rights to such application under this AGREEMENT
shall terminate in their entirety; provided, however, that if LICENSEE files and maintains patents in the MAJOR MARKET. COUNTRIES, UTMDACC may not terminate LICENSEE’s rights to applications filed in other jurisdictions. UTMDACC will provide
LICENSEE with a copy of the application for which LICENSEE has paid the cost of filing, as well as copies of any documents received or filed during prosecution thereof. UTMDACC shall consult with LICENSEE in a timely manner concerning (i) scope
and content of all patent applications within the PATENT RIGHTS prior to filing such patent applications, and (ii) content of and proposed responses to official actions of the United States Patent and Trademark Office and foreign patent offices
during prosecution of any patent applications within the PATENT RIGHTS. For purposes of this Paragraph 6.1, “timely” shall mean sufficiently in advance of any decision by UTMDACC or any deadline imposed upon written response by UTMDACC so
as to allow LICENSEE to meaningfully review such decision or written response and also provide comments to UTMDACC in advance of such decision or deadline to allow comments of LICENSEE respect to the PATENT RIGHTS to be considered and incorporated
into 

  
 15 

 
UTMDACC’s decision or written response. The parties agree that they share a common legal interest to get valid enforceable patents and that LICENSEE will keep all privileged information
received pursuant to this Section confidential. 
 6.2 With respect to the filing of any patent application within the PATENT RIGHTS, or the
prosecution of any patent application within the PATENT RIGHTS, or the maintenance of any patent within the PATENT RIGHTS, if UTMDACC elects not to file for or continue prosecution of any such patent application or maintain any such patent, UTMDACC
shall promptly notify LICENSEE in writing sufficiently in advance of any deadline to enable LICENSEE to file for or continue prosecution of such patent application and/or maintain such patent, and in such event LICENSEE (or its designee) may at its
discretion pursue such filing, prosecution and/or maintenance of its own expense in UTMDACC’s name. 
 VII. PATENT MARKING 

7.1 LICENSEE agrees that all packaging containing individual LICENSED PRODUCT(S), documentation therefor, and, when possible, actual LICENSED
PRODUCT(S) sold by LICENSEE, AFFILIATES, and/or SUBLICENSEES of LICENSEE will be permanently and legibly marked with the number of any applicable patent(s) licensed hereunder in accordance with each country’s patent laws, including
Title 35, United States Code. 
 VIII. INDEMNIFICATION AND INSURANCE 

8.1 LICENSEE agrees to hold harmless and indemnify BOARD, SYSTEM, UTMDACC, their Regents, officers, employees, students and agents from and
against any claims, demands, or causes of action whatsoever, costs of suit and reasonable attorney’s fees, including without limitation, those costs arising on account of any injury or death of persons or damage to property caused by, or
arising out of, or resulting from, the exercise or practice of the rights granted hereunder by LICENSEE, its officers, its AFFILIATES or their officers, employees, agents or representatives. 

  
 16 

 8.2 In no event shall BOARD, SYSTEM or UTMDACC be liable for any indirect, special, consequential
or punitive damages (including, without limitation, damages for los of profits or expected savings or other economic loses, or for injury to persons or property) arising out of, or in connection with, this AGREEMENT or its subject mater, regardless
of whether BOARD, SYSTEM or UTMDACC knows or should know of the possibility of such damages. 
 8.3 Beginning at the time when any LICENSED
SUBJECT MATER is being distributed or sold (including for the purpose of obtaining regulatory approvals) by LICENSEE, an AFFILIATE, or by a SUBLICENSEE, LICENSEE shall, at its sole cost and expense, procure and maintain commercial general liability
insurance in amounts not les than $2,00,00 per incident and $2,00,00 annual aggregate, and LICENSEE shall use reasonable efforts to have the BOARD, SYSTEM, UTMDACC, their Regents, officers, employees, students and agents named as additional
insureds. Such commercial general liability insurance shall provide: (1) product liability coverage; (i) broad form contractual liability coverage for LICENSEE’s indemnification under this AGREEMENT; and (iii) coverage for
litigation costs. The minimum amounts of insurance coverage required herein shall not be construed to create a limit of LICENSEE’s liability with respect to its indemnification under this AGREEMENT. 

8.4 LICENSEE shall provide UTMDACC with written evidence of such insurance within thirty (30) calendar days of its procurement.
Additionally, LICENSEE shall provide UTMDACC with written notice of at least fifteen (15) calendar days prior to the cancellation, non-renewal or material change in such insurance. 

  
 17 

 8.5 LICENSEE shall maintain such commercial general liability insurance beyond the expiration or
termination of this AGREEMENT during: (i) the period that any LICENSED PRODUCTS developed pursuant to this AGREEMENT are being commercially distributed or sold by LICENSEE, an AFFILIATE or by a SUBLICENSEE of LICENSEE; and (ii) the five
(5) year period immediately after such period. 
 IX. USE OF BOARD AND UTMDACC’S NAME 

9.1 LICENSEE will not use the name of {or the name of any employee of) UTMDACC, SYSTEM or BOARD in any advertising, promotional or sales
literature, on its Web site, or for the purpose of raising capital without the advance express written consent of BOARD secured through: 

The University of Texas 
 M. D.
Anderson Cancer Center 
 Legal Services, Unit 0537 

P.O. Box 301439 
 Houston, TX
77230-1439 
 ATTENTION: Natalie Wright 

Email: nwright@mdanderson.org 

Notwithstanding the above, LICENSEE may use the name of (or name of employee of) UTMDACC, SYSTEM or BOARD in routine business correspondence,
or as needed in appropriate regulatory submissions without express written consent, including when indicating, as a factual matter, that UTMDACC, SYSTEM or BOARD is a licensor of LICENSEE under this AGREEMENT in connection with either or both of the
following: 
 (a) communications associated with LICENSEE’s financing activities; and 

(b) communications (other than promotions and advertisements) directed to describing or responding to inquiries concerning the business,
technology, products, services and associated activities of LICENSEE. 

  
 18 

 X. CONFIDENTIAL INFORMATION AND PUBLICATION 

10.1 UTMDACC and LICENSEE each agree that all information contained in documents marked “confidential” and forwarded to one by the
other (i) are to be received in strict confidence, (ii) are to be used only for the purposes of this AGREEMENT, and (iii) will not be disclosed by the recipient party (except as required by law or court order), its agents or employees
without the prior written consent of the disclosing party, except to the extent that such information: 
 (a) was in the public domain at
the time of disclosure; or 
 (b) later became part of the public domain through no act or omission of the recipient party, its employees,
agents, successors or assigns; or 
 (c) was lawfully disclosed to the recipient party by a third party having the right to disclose it; or

 (d) was already known by the recipient party at the time of disclosure, as demonstrated by competent written proof (such as
contemporaneous records); or 
 (e) was independently developed by the recipient party without use of the disclosing party’s
confidential information, as demonstrated by competent written proof (such as contemporaneous records); or 
 (f) is required by law or
regulation to be disclosed. 
 Notwithstanding the foregoing, LICENSEE may disclose any LICENSED SUBJECT MATTER comprising the confidential
information of UTMDACC to third parties pursuant to a commercially reasonable confidentiality agreement, or otherwise in connection with the exercise of its license rights under this AGREEMENT. 

  
 19 

 10.2 Each party’s obligation of confidence hereunder will be fulfilled by using at least the
same degree of care with the disclosing party’s confidential information as it uses to protect its own confidential information, but always at least a reasonable degree of care. This obligation will exist while this AGREEMENT is in force and
for a period of three (3) years thereafter. 
 XI. ASSIGNMENT 

11.1 Except in connection with the sale of all or substantially all of LICENSEE’s business or assets relating to this AGREEMENT to a
third party, this AGREEMENT may not be assigned by LICENSEE without the prior written consent of UTMDACC, which will not be unreasonably withheld. 

XII. TERM AND TERMINATION 

12.1 Subject to Sections 12.2 and 12.3 hereinbelow, the term of this AGREEMENT is from the EFFECTIVE DATE to the full end of the term or
terms for which PATENT RIGHTS have not expired, been revoked or invalidated, provided that LICENSEE’s license with respect to the TECHNOLOGY RIGHTS shall survive the expiration of this AGREEMENT and be considered fully-paid up. 

12.2 Subject to any rights herein which survive termination, this AGREEMENT will earlier terminate in its entirety: 

(a) automatically, if LICENSEE becomes bankrupt and/or if the business of LICENSEE shall be placed in the hands of a receiver, assignee, or
trustee, whether by voluntary act of LICENSEE or otherwise; or 
 (b) upon thirty (30) calendar days written notice from UTMDACC, if
LICENSEE breaches or defaults on the payment or report obligations of ARTICLE IV, or use of name obligations of ARTICLE IX, unless, before the end of the such thirty (30)-calendar day notice period, LICENSEE
has cured the default or breach, and so notifies UTMDACC, stating the manner of the cure; or 

  
 20 

 (c) upon ninety (90) calendar days written notice from UTMDACC if LICENSEE breaches or
defaults on any other material obligation under this AGREEMENT, unless, before the end of the such ninety (90) calendar-day notice period, LICENSEE has cured the default or breach and so notifies UTMDACC, stating the manner of the cure; or 

(d) at any time by mutual written agreement between LICENSEE and UTMDACC upon one hundred eighty (180) calendar days written notice to
all parties and subject to any terms herein which survive termination; or 
 (e) upon thirty (30) calendar days written notice from
LICENSEE to UTMDACC of LICENSEE’S intent to terminate, which notice LICENSEE may provide (i) for any reason or no reason, and (ii) with respect to the AGREEMENT in its entirety or with respect to any family of patents or patent
applications within the PATENT RIGHTS that correspond to an individual MDA case number. 
 Notwithstanding the foregoing, if before the end
of the applicable cure period of Section 12.2(b) or (c) above, LICENSEE disputes the breach or default claimed by UTMDACC, UTMDACC shall not have the right to terminate this AGREEMENT unless and until the parties have completed the dispute
resolution procedure outlines in Section 14.6, LICENSEE is found to have materially breached this AGREEMENT, and LICENSEE fails to cure such breach within the applicable cure period following such determination; provided that the foregoing
shall not suspend any obligation of LICENSEE to pay to UTMDACC any undisputed amount owed by LICENSEE to UTMDACC under this AGREEMENT, during the pendency of any determination of breach. 

  
 21 

 
Additionally, UTMDACC can terminate according to Section 12.2(b) above if it is for nonpayment of patent expenses pursuant to Section 4.1(a) or nonpayment of milestone fees pursuant to
Section 4.1(b). 
 12.3 Upon termination of this AGREEMENT: 

(a) nothing herein will be construed to release either party of any obligation maturing prior to the effective date of the termination; and

 (b) the parties covenant and agree to be bound by the provisions of Articles VIII (Indemnification and Insurance), IX (Use of Board and
UTMDACC’s Name) and X (Confidential Information and Publication) of this AGREEMENT, and any other provisions that by their nature or as otherwise provided herein, are intended to survive this AGREEMENT; and 

(c) LICENSEE may, for a period of one year after the effective date of the termination, sell all LICENSED PRODUCTS and parts therefor that it
has on hand at the date of termination, if LICENSEE pays the earned royalty thereon arid any other amounts due pursuant to Article IV of this AGREEMENT; and 

(d) Subject to Sections, 3.5, 12.1 and 12.3(c), the license granted to LICENSEE under Section 3.1 shall terminate and LICENSEE agrees to
cease and desist any use and all SALE of the LICENSED SUBJECT MATTER and LICENSED PRODUCTS upon termination of this AGREEMENT. 
 XIII.
WARRANTY: SUPERIOR-RIGHTS 
 13.1 Except for the rights, if any, of the Government of the United States of America as set forth below,
BOARD represents and warrants its belief that (a) it is the owner of the entire right, title, and interest in and to LICENSED SUBJECT MATTER, (b) it has the sole right to grant licenses thereunder, and (c) it has not knowingly granted
licenses thereunder to any other entity that would restrict rights granted hereunder except as stated herein. 

  
 22 

 13.2 LICENSEE understands that the LICENSED SUBJECT MATTER may have been developed under a
funding agreement with the Government of the United States of America (“Government”) and, if so, that the Government may have certain rights relative thereto. This AGREEMENT is explicitly made subject to the Government’s rights under
any such agreement and any applicable law or regulation. To the extent that there is a conflict between any such agreement, applicable law or regulation and this AGREEMENT, the terms of such Government agreement, applicable law or regulation shall
prevail. To the extent required by applicable law or regulation, LICENSEE agrees that LICENSED PRODUCTS used or SOLD in the United States will be manufactured substantially in the United States, unless a written waiver is obtained in advance from
the GOVERNMENT. LICENSEE will promptly advise UTMDACC if such a written waiver is requested and/or obtained. 
 13.3 LICENSEE understands
and agrees that BOARD and UTMDACC, by this AGREEMENT, make no representation as to the operability or fitness for any use, safety, efficacy, approvability by regulatory authorities, time and cost of development, patentability, and/or breadth of the
LICENSED SUBJECT MATTER. BOARD and UTMDACC, by this AGREEMENT, also make no representation as to whether any patent covered by PATENT RIGHTS is valid or as to whether there are any patents now held, or which will be held, by others or by BOARD or
UTMDACC in the LICENSED FIELD, nor do BOARD and UTMDACC make any representation that the inventions contained in PATENT RIGHTS do not infringe any other patents now held or that will be held by others or by BOARD. 

  
 23 

 13.4 LICENSEE, by execution hereof, acknowledges, covenants and agrees that LICENSEE has not been
induced in any way by BOARD, SYSTEM, UTMDACC or employees thereof to enter into this AGREEMENT and LICENSEE is entering into this AGREEMENT voluntarily. 

XIV. GENERAL 
 14.1 This
AGREEMENT constitutes the entire and only agreement between the parties for LICENSED SUBJECT MATTER and all other prior negotiations, representations, agreements and understandings are superseded hereby. No agreements altering or supplementing the
terms hereof will be made except by a written document signed by both parties. 
 14.2 Any notice required by this AGREEMENT must be given
by prepaid, first class, certified mail, return receipt requested, and addressed in the case of UTMDACC to: 
 The University of Texas M. D.
Anderson Cancer Center 
 Office of Technology Commercialization 

7515 S. Main, Suite 490, Unit 0510 

Houston, Texas 77030 
 ATTENTION:
Christopher C. Capelli, M.D. 
 or in the case of LICENSEE to: 

Introgen Therapeutics, Inc. 
 301
Congress, Suite 1850 
 Austin, Texas 78701 

ATTENTION: David Nance 
 or other
addresses as may be given from time to time under the terms of this notice provision. 
 14.3 LICENSEE must comply with all applicable
federal, state and local laws and regulations in connection with its activities pursuant to this AGREEMENT, 
 14.4 LICENSEE acknowledges
that the LICENSED SUBJECT MATTER is subject to U. S. export control jurisdiction. LICENSEE agrees to comply with all applicable international and 

  
 24 

 
national laws that apply to the LICENSED SUBJECT MATTER, including U.S. Export Administration Regulations, as well as end-user, end-use, and destination restrictions applied by the United States.

 14.5 This AGREEMENT will be construed and enforced in accordance with the laws of the United States of America and of the State of Texas,
without regard to its conflict of law provisions. The Texas State Courts of Harris County, Texas (or, if there is exclusive federal jurisdiction, the United States District Court for the Southern District of Texas) shall have exclusive jurisdiction
and venue over any dispute arising out of this AGREEMENT, and LICENSEE consents to the jurisdiction of such courts; however, nothing in this AGREEMENT shall be deemed as a waiver by BOARD, SYSTEM or UTMDACC of its sovereign immunity. 

14.6 Certain disputes arising out of or relating to this AGREEMENT, its construction or its actual or alleged breach may be decided by
mediation. If the mediation does not result in a resolution of such dispute or controversy, it will be finally decided by binding arbitration, conducted in the city of Houston, Harris County, Texas, in accordance with the applicable, then-current
procedures of the American Arbitration Association. The arbitration panel will include members knowledgeable in the evaluation of the LICENSED SUBJECT MATTER. Judgment upon the award rendered may be entered in the highest court or forum having
jurisdiction, state or federal. The provisions of this Section 14.6 will not apply to decisions on the validity of patent claims or to any dispute or controversy as to which any treaty or law prohibits such arbitration. Notwithstanding the
foregoing, the decision of the arbitration must be sanctioned by a court of law having jurisdiction to be binding upon and enforceable by the parties. 

  
 25 

 14.7 Failure of BOARD or UTMDACC to enforce a right under this AGREEMENT will not act as a waiver
of right or the ability to later assert that right relative to the particular situation involved. 
 14.8 Headings included herein are for
convenience only and will not be used to construe this AGREEMENT. 
 14.9 If any part of this AGREEMENT is for any reason found to be
unenforceable, all other parts nevertheless will remain enforceable. 
 14.10 In the event that LICENSEE brings an action before any court,
agency or tribunal seeking to invalidate or otherwise challenge the enforceability of or BOARD’s ownership of any patent included in the PATENT RIGHTS, then UTMDACC may immediately terminate this AGREEMENT upon written notice to LICENSEE.
Additionally, LICENSEE will provide written notice to UTMDACC at least three (3) months prior to seeking to invalidate or challenge any patent under the PATENT RIGHTS. LICENSEE will include with such written notice an identification of all
prior art it believes invalidates any claim of a patent under the PATENT RIGHTS and will promptly update such disclosure as LICENSEE becomes aware of additional prior art. Any dispute regarding the validity, enforceability or ownership of any patent
included in the PATENT RIGHTS shall be litigated in the courts located in Houston, Texas, and LICENSEE agrees not to challenge personal jurisdiction in that forum. To the extent that LICENSEE unsuccessfully challenges the validity or enforceability
of any patent included in the PATENT RIGHTS, LICENSEE agrees to reimburse UTMDACC and BOARD for all costs and fees (including attorney’s fees) paid by UTMDACC and BOARD in defending against such challenge. LICENSEE understands and agrees that,
in the event LICENSEE successfully challenges the validity or enforceability of any patent included in the PATENT RIGHTS, all payments or other consideration made or otherwise provided by LICENSEE to UTMDACC prior to a final, non-appealable
adjudication of invalidity and/or unenforceability shall be non-refundable. The obligations of this Section shall survive the expiration or termination of this AGREEMENT. 

  
 26 

 IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives
to execute this AGREEMENT. 
  

									
	 BOARD OF REGENTS OF THE
 UNIVERSITY
OF TEXAS SYSTEM
	 		 		 	INTROGEN THERAPEUTICS, INC.
					
	By	 	  
	 		 	By	 	  

		 	John Mendelsohn, M.D.	 		 	Name:	 	  

		 	President	 		 	Title:	 	  

		 	The University of Texas	 		 		 	
		 	M. D. Anderson Cancer Center	 		 		 	
					
	Date:	 	  
	 		 	Date:	 	  

				
	 THE UNIVERSITY OF TEXAS
 M. D.
ANDERSON CANCER CENTER
	 		 		 	
					
	By	 	  
	 		 		 	
		 	Leon Leach	 		 		 	
		 	Executive Vice President	 		 		 	
		 	The University of Texas	 		 		 	
		 	M. D. Anderson Cancer Center	 		 		 	
					
	Date:	 	  
	 		 		 	
				
	Approved as to Content:	 		 		 	
					
	By	 	  
	 		 		 	
		 	Christopher C. Capelli	 		 		 	
		 	Vice President, Technology Transfer	 		 		 	
		 	M. D. Anderson Cancer Center	 		 		 	
					
	Date:	 	  
	 		 		 	

  

  
 27 

 EXHIBIT I 
  

  
 28 

 Attachment C-1 

Terms for Exclusive License Agreement 

For Institution Inventions related to the use, manufacture or composition of any Material, the following ranges will apply: 

License Documentation Fee under Section 4.1(b) shall be consistent with the following: 

 

	 	•	 	Between $[***] and $[***] 

 Annual Maintenance Fees under Section 4.1(c) shall be
consistent with the following: 
  

	 	•	 	Between $[***] and $[***] (years 1-4) 

  

	 	•	 	Between $[***] and $[***] (years 4 and beyond) 

 Running Royalties under Section 4.1(d)
shall be consistent with the following: 
  

	 	•	 	Between [***]% and [***]% for therapeutic products 

  

	 	•	 	Between [***]% and [***]% for diagnostic products 

  

	 	•	 	Between [***]% and [***]% for all other products 

 Minimum Annual Royalty after first Sale under
Section 4.1(e) shall be consistent with the following: 
  

	 	•	 	Between $[***] and $[***] 

 Percentage of Sublicensing Income payable under Section 4.1(0
shall be consistent with the following: 
  

	 	•	 	Between [***]% and [***]% (year 1) 

  

	 	•	 	Between [***]% and [***]% (additional years) 

 For other Institution Inventions: 

License Documentation Fee under Section 4.1(b) shall be consistent with the following: 

 

	 	•	 	Between $[***] and $[***] 

 Annual Maintenance Fees under Section 4.1(c) shall be
consistent with the following: 
  

	 	•	 	Between $[***] and $[***] (years 1-4) 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 1 

	 	•	 	Between $[***] and $[***] (years 4 and beyond) 

 Running Royalties under Section 4.1(d)
shall be consistent with the following: 
  

	 	•	 	Between [***]% and [***]%for therapeutic products 

  

	 	•	 	Between [***]% and [***]% for diagnostic products 

  

	 	•	 	Between [***]% and [***]% for all other products 

 Minimum Annual Royalty after first Sale under
Section 4.1(e) shall he consistent with the following: 
  

	 	•	 	Between $[***] and $[***] 

 Percentage of Sublicensing Income payable under Section 4.1(0
shall be consistent with the following: 
  

	 	•	 	Between [***]% and [***]% (year 1) 

  

	 	•	 	Between [***]% and [***]% (additional years) 

 For Joint Inventions: 

License Documentation Fee under Section 4.1(b) shall be consistent with the following: 

 

	 	•	 	Between $[***] and $[***] 

 Annual Maintenance Fees under Section 4.1(c) shall be
consistent with the following: 
  

	 	•	 	Between $[***] and $[***] (years 1-4) 

  

	 	•	 	Between $[***] and $[***] (years 4 and beyond) 

 Running Royalties under Section 4.1(d)
shall be consistent with the following: 
  

	 	•	 	Between [***]% and [***]% for therapeutic products 

  

	 	•	 	Between [***]% and [***]% for diagnostic products 

  

	 	•	 	Between [***]% and [***]% for all other products 

 Minimum Annual Royalty after first Sale under
Section 4.1(e) shall be consistent with the following: 
  

	 	•	 	Between $[***] and $[***] 

 Percentage of Sublicensing Income payable under Section 4.1(f)
shall be consistent with the following: 
  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 2 

	 	•	 	Between [***]% and [***]% (year 1) 

  

	 	•	 	Between [***]% and [***]% (additional years) 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 3 

 Attachment C-2 

Terms for Non-Exclusive License Agreement 

For Institution Inventions related to the use, manufacture or composition of any Material, the following ranges will apply: 

Milestone #1 under Section 4.1(a) shall be consistent with the following: 

 

	 	•	 	Between $[***] and $[***] 

 Milestone #2 under Section 4.19a) shall be consistent with the
following: 
  

	 	•	 	Between $[***] and $[***] 

 Running Royalties under Section 4.1(b) shall be consistent with
the following: 
  

	 	•	 	Between [***]% and [***]% for therapeutic products 

  

	 	•	 	Between [***]% and [***]% for diagnostic products 

  

	 	•	 	Between [***]% and [***]% for all other products 

 Percentage of Sublicensing Income payable
under Section 4.1(c) shall be consistent with the following: 
  

	 	•	 	Between [***]% and [***]% (year 1) 

  

	 	•	 	Between [***]% and [***]% (additional years) 

 For other Institution Inventions: 

Milestone #1 under Section 4.1(a) shall be consistent with the following: 

 

	 	•	 	Between $[***] and $[***] 

 Milestone #2 under Section 4.1(a) shall be consistent with the
following: 
  

	 	•	 	Between $[***] and $[***] 

 Running Royalties under Section 4.1(b) shall be consistent with
the following: 
  

	 	•	 	Between [***]% and [***]% for therapeutic products 

  

	 	•	 	Between [***]% and [***]% for diagnostic products 

  

	 	•	 	Between [***]% and [***]% for all other products 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 1 

 Percentage of Sublicensing Income payable under Section 4.1(c) shall be consistent with the
following: 
  

	 	•	 	Between [***]% and [***]% (year 1) 

  

	 	•	 	Between [***]% and [***]% (additional years) 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

  
 2EX-10.27

 Exhibit 10.27 

C  Confidential 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

NON-EXCLUSIVE LICENSE AGREEMENT 

by and between 
 MERCK
SHARP & DOHME CORP. 
 and 

P53 INC. 

 C  Confidential 

CONFIDENTIAL TREATMENT REQUESTED 

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN 

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION 

NON-EXCLUSIVE LICENSE AGREEMENT 

This Non-Exclusive License Agreement (this “Agreement”), effective as of the date of last signature hereto (the
“Effective Date”), is entered into by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey, having a place of business at One Merck Drive, P.O. Box 100, Whitehouse
Station, New Jersey 08889 (“Merck”) and P53 INC., a corporation organized and existing under the laws of Delaware, having a place of business at 2000 Edwards Street, Houston, TX 77007 (“P53”). 

RECITALS: 

WHEREAS, Merck owns Merck Data (defined below); and 

WHEREAS, P53 desires to obtain a license to the Merck Data and Merck desires to grant such license upon the terms and conditions set
forth herein. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for
good and valuable consideration, the receipt and sufficiency which are hereby acknowledged, Merck and P53 hereby agree as follows: 

ARTICLE 1 DEFINITIONS 

Unless specifically set forth to the contrary in this Agreement, the following terms, whether used in the singular or plural, shall have the
respective meanings set out below. 
 1.1 “ACCEPTANCE” MEANS THE REGULATORY AUTHORITY HAS DEEMED THAT THE INCLUSION OF THE
MERCK DATA IN AN IND FOR PRODUCT FILED BY P53 OR ITS RELATED PARTIES IS ACCEPTABLE FOR THE PURPOSE OF GRANTING REGULATORY APPROVAL. 
 1.2
“ACT” MEANS AS APPLICABLE, THE UNITED STATES FEDERAL FOOD, DRUG AND COSMETIC ACT, 21 U.S.C. §§ 301 ET SEQ., AND/OR THE PUBLIC HEALTH SERVICE ACT, 42 U.S.C. §§ 262 ET SEQ., AS SUCH MAY BE AMENDED FROM
TIME TO TIME. 
 1.3 “ADVEXIN” MEANS P53’S ADENOVIRAL PRODUCT FOR THE THERAPEUTIC TREATMENT OF HUMAN PATIENTS WITH
COLORECTAL CANCER. 
 1.4 “AFFILIATE” OF A PARTY MEANS (I) ANY CORPORATION OR BUSINESS ENTITY OF WHICH FIFTY PERCENT
(50%) OR MORE OF THE SECURITIES OR OTHER OWNERSHIP INTERESTS REPRESENTING THE EQUITY, THE VOTING STOCK OR GENERAL PARTNERSHIP INTEREST ARE OWNED, CONTROLLED OR 

 C  Confidential 

 
 
HELD, DIRECTLY OR INDIRECTLY, BY THE PARTY; OR (II) ANY CORPORATION OR BUSINESS ENTITY WHICH, DIRECTLY OR INDIRECTLY, OWNS, CONTROLS OR HOLDS FIFTY PERCENT (50%) (OR THE MAXIMUM
OWNERSHIP INTEREST PERMITTED BY LAW) OR MORE OF THE SECURITIES OR OTHER OWNERSHIP INTERESTS REPRESENTING THE EQUITY, THE VOTING STOCK OR, IF APPLICABLE, THE GENERAL PARTNERSHIP INTEREST, OF THE PARTY; OR (III) ANY CORPORATION OR BUSINESS ENTITY
OF WHICH FIFTY PERCENT (50%) OR MORE OF THE SECURITIES OR OTHER OWNERSHIP INTERESTS REPRESENTING THE EQUITY, THE VOTING STOCK OR GENERAL PARTNERSHIP INTEREST ARE OWNED, CONTROLLED OR HELD, DIRECTLY OR INDIRECTLY, BY A CORPORATION OR BUSINESS
ENTITY DESCRIBED IN (I) OR (II). 
 1.5 “CALENDAR QUARTER” MEANS THE RESPECTIVE PERIODS OF THREE (3) CONSECUTIVE
CALENDAR MONTHS ENDING ON MARCH 31, JUNE 30, SEPTEMBER 30 AND DECEMBER 31. 
 1.6 “CALENDAR YEAR” MEANS
EACH SUCCESSIVE PERIOD OF TWELVE (12) MONTHS STARTING ON JANUARY 1 AND ENDING ON DECEMBER 31. 
 1.7 “FIRST
COMMERCIAL SALE” SHALL MEAN THE FIRST COMMERCIAL SALE BY P53 OR ITS RELATED PARTIES OF PRODUCT, IN ANY COUNTRY, AFTER A GRANT OF MARKETING AUTHORIZATION FOR SUCH PRODUCT IN SUCH COUNTRY. 

1.8 “IND” MEANS AN INVESTIGATIONAL NEW DRUG APPLICATION, CLINICAL STUDY APPLICATION, CLINICAL TRIAL EXEMPTION, OR SIMILAR
APPLICATION OR SUBMISSION FOR APPROVAL TO CONDUCT HUMAN CLINICAL INVESTIGATIONS UTILIZING PRODUCT FILED WITH OR SUBMITTED TO A REGULATORY AUTHORITY IN CONFORMANCE WITH THE REQUIREMENTS OF SUCH REGULATORY AUTHORITY. 

1.9 “INFORMATION” MEANS ANY AND ALL INFORMATION AND DATA, INCLUDING THE MERCK DATA, AND ALL OTHER SCIENTIFIC, PRE-CLINICAL,
CLINICAL, REGULATORY, MANUFACTURING, MARKETING, FINANCIAL AND COMMERCIAL INFORMATION OR DATA, WHETHER COMMUNICATED IN WRITING OR ORALLY OR BY ANY OTHER METHOD, WHICH IS PROVIDED BY ONE PARTY TO THE OTHER PARTY IN CONNECTION WITH THIS AGREEMENT. 

1.10 “MARKETING AUTHORIZATION” SHALL MEAN ANY APPROVAL NECESSARY FROM THE RELEVANT REGULATORY AUTHORITY TO MARKET AND SELL
PRODUCT IN ANY COUNTRY. 
 1.11 “MERCK DATA” MEANS THE DATA GENERATED UNDER THE STUDIES TITLED “GENE THERAPY OF
PRIMARY AND METASTATIC MALIGNANT TUMORS OF THE LIVER USING SCH 58500 (RAD/P53) VIA HEPATIC ARTERY 

  
 2 

 C  Confidential 

 
 
INFUSION: A PHASE I STUDY” (PROTOCOL C95-063) AND “A PHASE 2 STUDY OF SCH 058500 IN COMBINATION WITH CHEMOTHERAPY AND CHEMOTHERAPY ALONE IN PATIENTS WITH COLORECTAL CANCER
METASTATIC TO THE LIVER” (PROTOCOL C98-118) BOTH ATTACHED HERETO AS ATTACHMENT A. 
 1.12 “NET SALES” MEANS
THE GROSS INVOICE PRICE OF PRODUCT, OR PACKAGE, (AS DEFINED BELOW) AS THE CASE MAY BE, SOLD BY P53 OR ITS RELATED PARTIES TO THIRD PARTIES DURING EACH CALENDAR QUARTER, LESS THE FOLLOWING AMOUNTS INCURRED OR PAID BY P53 OR SUCH RELATED PARTIES
DURING SUCH CALENDAR QUARTER WITH RESPECT TO SALES OF PRODUCT (OR PACKAGE, AS THE CASE MAY BE) REGARDLESS OF THE CALENDAR QUARTER IN WHICH SUCH SALES WERE MADE (COLLECTIVELY, THE “GROSS INVOICE PRICE DEDUCTIONS”): 

(a) TRADE, CASH AND QUANTITY DISCOUNTS OR REBATES ACTUALLY ALLOWED OR TAKEN, INCLUDING DISCOUNTS OR REBATES TO GOVERNMENTAL OR MANAGED CARE
ORGANIZATIONS; 
 (b) CREDITS OR ALLOWANCES ACTUALLY GIVEN OR MADE FOR REJECTION OF, AND FOR UNCOLLECTIBLE AMOUNTS ON, OR RETURN OF
PREVIOUSLY SOLD PRODUCTS (OR PACKAGES, AS THE CASE MAY BE) (INCLUDING MEDICARE AND SIMILAR TYPES OF REBATES); 
 (c) ANY CHARGES FOR
INSURANCE, FREIGHT, AND OTHER TRANSPORTATION COSTS DIRECTLY RELATED TO THE DELIVERY OF PRODUCTS (OR PACKAGES, AS THE CASE MAY BE) TO THE EXTENT INCLUDED IN THE GROSS INVOICED SALES PRICE; 

(d) ANY TAX, TARIFF, DUTY OR GOVERNMENTAL CHARGE LEVIED ON THE SALES, TRANSFER, TRANSPORTATION OR DELIVERY OF A PRODUCT (OR PACKAGE, AS THE
CASE MAY BE) (INCLUDING ANY TAX SUCH AS A VALUE ADDED OR SIMILAR TAX OR GOVERNMENT CHARGE) BORNE BY THE SELLER THEREOF, OTHER THAN FRANCHISE OR INCOME TAX OF ANY KIND WHATSOEVER; AND 

(e) ANY IMPORT OR EXPORT DUTIES OR THEIR EQUIVALENT BORNE BY P53 OR SUCH RELATED PARTIES. 

Under no circumstance shall Gross Invoice Price Deductions exceed five percent (5.0%) of the gross invoice price for each Product. 

In the event one or more Product(s) is/are sold together with one or more other product(s) as part of a kit or a package of products and/or
services (e.g., an instrument rental agreement with a Third Party) (a “Package”), Net Sales for purposes of determining the royalty payments under this Agreement for such Package (the “Package Net Sales”) shall be
determined 

  
 3 

 C  Confidential 

 
 
by multiplying the Net Sales of the Package by the fraction A/[A+B], where A is the gross selling price during of the Product when sold separately in the country of sale of the Package during the
period in which the sale was made, and B is the gross selling price during the same period and in the same country, of the Package not containing the Product; or in the event that no such separate sales are made of the Product, Net Sales for
purposes of determining the royalty payments under this Agreement shall be calculated by multiplying the Net Sales of the Package by the fraction C/[C+D], where C is the standard fully absorbed cost to the Party (or Affiliate or Sublicensee, as the
case may be) selling the Product of the Product portion of such Package and D is the standard fully absorbed cost to the Party (or Sublicensee, as the case may be) selling the Package not containing the Product, such costs being determined by using
such Party’s (or Affiliate’s or Sublicensee’s, as the case may be) standard accounting procedures, applied on a consistent basis in accordance with U.S. generally accepted accounting principles. If no separate costs may be determined
of the Product or the Package not containing the Product, P53 and Merck shall agree in good faith upon the Package Net Sales based upon a fair market price for that Package, which agreed upon price shall be used to calculate Net Sales. For purposes
of clarity, Gross Invoice Price Deductions for any Package shall not exceed five percent (5%) of the gross sales price for the Package. 

1.13 “PARTY” MEANS MERCK AND P53, INDIVIDUALLY, AND “PARTIES” SHALL MEAN MERCK AND P53, COLLECTIVELY. 

1.14 “PHASE II CLINICAL TRIAL” MEANS A HUMAN CLINICAL TRIAL IN ANY COUNTRY THAT WOULD SATISFY THE REQUIREMENTS OF 21
CFR 312.21(B). 
 1.15 “PRODUCT” MEANS (I) ADVEXIN AND/OR (II) ANY PHARMACEUTICAL AND/OR BIOLOGICAL PRODUCT IN
WHICH THE IND FOR SUCH PRODUCT CONTAINS THE MERCK DATA. 
 1.16 “REGULATORY APPROVAL” MEANS ANY APPROVAL FROM THE RELEVANT
REGULATORY AUTHORITY NECESSARY FOR THE USE OF A PRODUCT IN A PHASE II CLINICAL TRIAL IN THE APPLICABLE COUNTRY. 
 1.17 “REGULATORY
AUTHORITY” MEANS ANY APPLICABLE GOVERNMENT REGULATORY AUTHORITY INVOLVED IN GRANTING APPROVALS FOR THE MANUFACTURING, MARKETING, REIMBURSEMENT AND/OR PRICING OF A PRODUCT IN THE TERRITORY, INCLUDING, IN THE UNITED STATES, THE UNITED STATES
FOOD AND DRUG ADMINISTRATION AND ANY SUCCESSOR GOVERNMENTAL AUTHORITY HAVING SUBSTANTIALLY THE SAME FUNCTION. 
 1.18 “RELATED
PARTIES” MEANS WITH RESPECT TO MERCK, ITS AFFILIATES, AND WITH RESPECT TO P53, ITS AFFILIATES AND SUBLICENSEES, AS APPLICABLE. 

  
 4 

 C  Confidential 

 
 1.19 “SUBLICENSEES” MEANS THIRD PARTIES ENGAGED BY P53
OR ITS AFFILIATES TO MAKE, USE, SELL, OFFER TO SELL OR IMPORT PRODUCT(S) WITH OR ON BEHALF OF P53 AND/OR ITS AFFILIATES. 
 1.20
“TERRITORY” MEANS ALL OF THE COUNTRIES IN THE WORLD, AND THEIR TERRITORIES AND POSSESSIONS. 
 1.21 “THIRD
PARTY” MEANS AN ENTITY OTHER THAN MERCK AND ITS RELATED PARTIES AND P53 AND ITS RELATED PARTIES. 
 1.22 ADDITIONAL TERMS.
IN ADDITION TO THE FOREGOING, THE FOLLOWING TERMS SHALL HAVE THE MEANING DEFINED IN THE CORRESPONDING SECTIONS BELOW: 
  

			
	 Term
	  	 Section Defined

	 “AAA”
	  	8.6.1
	 “Change of Control”
	  	8.2  
	 “Merck Indemnitees”
	  	6.1  
	 “P53 Indemnitees”
	  	6.2  
	 “Claim”
	  	6.1  
	 “Market”
	  	3.2.1
	 “P53 Sublicense”
	  	4.4  

 ARTICLE 2 LICENSE 

2.1 LICENSE GRANT. 

2.1.1 MERCK HEREBY GRANTS TO P53 A NON-EXCLUSIVE, NON-SUBLICENSEABLE, ROYALTY BEARING LICENSE TO USE THE MERCK DATA IN AN IND FOR PRODUCT FOR
THE PURPOSE OF OBTAINING ACCEPTANCE OF THE MERCK DATA FOR SUCH PRODUCT. 
 2.1.2 P53 AGREES THAT THE LICENSE GRANTED TO IT UNDER THIS
AGREEMENT IS LIMITED TO THAT GRANTED IN SECTION 2.1.1. 
 2.2 NO IMPLIED LICENSE. EXCEPT AS SET FORTH IN THIS AGREEMENT, P53
SHALL NOT ACQUIRE ANY LICENSE OR OTHER INTELLECTUAL PROPERTY INTEREST, BY IMPLICATION OR OTHERWISE, IN ANY INFORMATION DISCLOSED TO IT UNDER THIS AGREEMENT BY MERCK OR ITS AFFILIATES. 

2.3 NOTIFICATION OF ACCEPTANCE. P53 SHALL PROMPTLY NOTIFY MERCK WHETHER OR NOT IT RECEIVES ACCEPTANCE BY THE APPLICABLE REGULATORY
AUTHORITY WITH RESPECT TO THE MERCK DATA FOR A PRODUCT. IN THE EVENT P53 RECEIVES ACCEPTANCE, THEN P53 SHALL PAY MERCK A ONE TIME UPFRONT PAYMENT AND ROYALTIES AS SET FORTH IN 

  
 5 

 C  Confidential 

 
 
ARTICLE 4. IF P53 DOES NOT RECEIVE ACCEPTANCE, (I) P53 SHALL RETURN TO MERCK ALL INFORMATION, INCLUDING BUT NOT LIMITED TO, THE MERCK DATA, PROVIDED BY MERCK HEREUNDER, AND ALL COPIES
THEREOF, AND (II) THE LICENSE GRANTED IN SECTION 2.1 SHALL TERMINATE. 
 ARTICLE 3 CONFIDENTIALITY AND PUBLICATION 

3.1 NONDISCLOSURE OBLIGATION. ALL INFORMATION DISCLOSED BY ONE PARTY TO THE OTHER PARTY HEREUNDER SHALL BE MAINTAINED IN CONFIDENCE BY
THE RECEIVING PARTY AND SHALL NOT BE DISCLOSED TO ANY THIRD PARTY (EXCEPT TO AFFILIATES AND SUBLICENSEES THAT HAVE A NEED TO KNOW) OR USED FOR ANY PURPOSE EXCEPT AS SET FORTH HEREIN WITHOUT THE PRIOR WRITTEN CONSENT OF THE DISCLOSING PARTY, EXCEPT
TO THE EXTENT THAT SUCH INFORMATION: 
 3.1.1 IS KNOWN BY THE RECEIVING PARTY AT THE TIME OF ITS RECEIPT, AND NOT THROUGH A PRIOR DISCLOSURE
BY THE DISCLOSING PARTY, AS DOCUMENTED BY THE RECEIVING PARTY’S BUSINESS RECORDS; 
 3.1.2 IS IN THE PUBLIC DOMAIN BY USE AND/OR
PUBLICATION BEFORE ITS RECEIPT FROM THE DISCLOSING PARTY, OR THEREAFTER ENTERS THE PUBLIC DOMAIN THROUGH NO FAULT OF THE RECEIVING PARTY; 

3.1.3 IS SUBSEQUENTLY DISCLOSED TO THE RECEIVING PARTY BY A THIRD PARTY WHO MAY LAWFULLY DO SO AND IS NOT UNDER AN OBLIGATION OF
CONFIDENTIALITY TO THE DISCLOSING PARTY; 
 3.1.4 IS DEVELOPED BY THE RECEIVING PARTY INDEPENDENTLY OF INFORMATION RECEIVED FROM THE
DISCLOSING PARTY, AS DOCUMENTED BY THE RECEIVING PARTY’S BUSINESS RECORDS; 
 3.1.5 IS DISCLOSED TO GOVERNMENTAL OR OTHER REGULATORY
AGENCIES IN ORDER TO OBTAIN PATENTS, TO GAIN REGULATORY APPROVAL OR MARKETING AUTHORIZATION, BUT SUCH DISCLOSURE MAY BE ONLY TO THE EXTENT REASONABLY NECESSARY TO OBTAIN SUCH PATENTS OR AUTHORIZATIONS; 

3.1.6 IS DEEMED NECESSARY BY THE RECEIVING PARTY TO BE DISCLOSED TO A RELATED PARTY FOR THE RESEARCH AND DEVELOPMENT, MANUFACTURE AND/OR
MARKETING OF PRODUCTS IN ACCORDANCE WITH THIS AGREEMENT ON THE CONDITION THAT SUCH RELATED PARTY AGREE TO BE BOUND BY THE CONFIDENTIALITY AND NON-USE PROVISIONS CONTAINED IN THIS AGREEMENT; 

  
 6 

 C  Confidential 

 
 3.1.7 IS DEEMED NECESSARY BY COUNSEL TO THE RECEIVING PARTY TO BE
DISCLOSED TO SUCH PARTY’S ATTORNEYS, INDEPENDENT ACCOUNTANTS OR FINANCIAL ADVISORS FOR THE SOLE PURPOSE OF ENABLING SUCH ATTORNEYS, INDEPENDENT ACCOUNTANTS OR FINANCIAL ADVISORS TO PROVIDE ADVICE TO THE RECEIVING PARTY, ON THE CONDITION THAT
SUCH ATTORNEYS, ACCOUNTANTS OR FINANCIAL ADVISORS AGREE TO BE BOUND BY THE CONFIDENTIALITY AND NON-USE PROVISIONS CONTAINED IN THIS AGREEMENT. 

Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are
published or available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the
receiving Party. 
 If a Party is required by judicial or administrative process to disclose Information that is subject to the
non-disclosure provisions of this Section 3.1 or Section 3.2, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure
obligations. Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this Section 31, and the Party disclosing Information pursuant to law or court
order shall take all steps reasonably necessary, including obtaining an order of confidentiality, to ensure the continued confidential treatment of such Information. 

3.2 PUBLICITY/USE OF NAMES. 

3.2.1 NO DISCLOSURE OF THE EXISTENCE, OR THE TERMS, OF THIS AGREEMENT (EXCEPT TO RELATED PARTIES THAT HAVE A NEED TO KNOW) MAY BE MADE BY
EITHER PARTY, AND NO PARTY SHALL USE THE NAME, TRADEMARK, TRADE NAME OR LOGO OF THE OTHER PARTY, ITS AFFILIATES OR THEIR RESPECTIVE EMPLOYEES IN ANY PUBLICITY, PROMOTION, NEWS RELEASE OR DISCLOSURE RELATING TO THIS AGREEMENT OR ITS SUBJECT MATTER,
WITHOUT THE PRIOR EXPRESS WRITTEN PERMISSION OF THE OTHER PARTY, EXCEPT (A) AS MAY BE REQUIRED BY LAW, (B) AS MAY BE REQUIRED BY ANY NATIONALLY RECOGNIZED SECURITIES EXCHANGE, QUOTATION SYSTEM OR OVER-THE-COUNTER MARKET (ON WHICH SUCH
PARTY HAS ITS SECURITIES LISTED OR TRADED) (EACH, A “MARKET”), (C) ON A NEED-TO-KNOW BASIS TO SUCH OTHER PARTY’S LEGAL AND FINANCIAL ADVISORS, (D) AS REASONABLY NECESSARY IN CONNECTION WITH AN ACTUAL OR POTENTIAL
(I) DEBT OR EQUITY FINANCING OF SUCH OTHER PARTY OR (II) CHANGE OF CONTROL INVOLVING SUCH OTHER PARTY. THE PARTIES SHALL AGREE IN ADVANCE WITH EACH OTHER ON THE TERMS OF THIS AGREEMENT TO BE REDACTED IN ANY MARKET FILINGS UNDER
SUBSECTION (B) ABOVE. IN THE EVENT P53 DESIRES TO DISCLOSE INFORMATION TO A THIRD PARTY AS PERMITTED UNDER SUBSECTIONS (C) OR (D), P53 SHALL MAKE CERTAIN THAT SUCH THIRD PARTY IS FIRST BOUND BY OBLIGATIONS OF CONFIDENTIALITY AND NON-USE AS
STRINGENT AS REQUIRED FOR EACH PARTY UNDER THIS AGREEMENT. 

  
 7 

 C  Confidential 

 
 ARTICLE 4 PAYMENT; ROYALTIES; REPORTS; AUDITS 

4.1 UPFRONT PAYMENT. WITHIN THIRTY (30) DAYS OF THE DATE OF FIRST ACCEPTANCE BY A REGULATORY AUTHORITY, P53 WILL PAY TO MERCK A
ONE-TIME, NON-REFUNDABLE PAYMENT EQUAL TO [***] ( $[***]). 
 4.2 ROYALTIES. P53 SHALL PAY MERCK ROYALTIES ON THE SALE OF PRODUCT BY
IT OR ITS RELATED PARTIES, CALCULATED ON A PRODUCT-BY-PRODUCT AND COUNTRY-BY-COUNTRY BASIS, IN AN AMOUNT EQUAL TO [***] ([***]%) OF WORLDWIDE NET SALES OF PRODUCT SOLD BY P53 OR ANY OF ITS RELATED PARTIES IN EACH CALENDAR YEAR. 

4.3 ROYALTY PERIOD. ROYALTIES ON EACH PRODUCT AT THE RATE SET FORTH ABOVE SHALL CONTINUE ON A PRODUCT-BY-PRODUCT AND COUNTRY-BY-COUNTRY
BASIS UNTIL A PERIOD OF [***]YEARS AFTER THE FIRST COMMERCIAL SALE OF SUCH PRODUCT IN SUCH COUNTRY. 
 4.4 PERFORMANCE BY RELATED
PARITIES. THE PARTIES RECOGNIZE THAT P53 MAY PERFORM SOME OR ALL OF ITS OBLIGATIONS OR EXERCISE SOME OR ALL OF ITS RIGHTS UNDER THIS AGREEMENT WITH RESPECT TO THE DEVELOPMENT, MANUFACTURE, AND COMMERCIALIZATION OF PRODUCT THROUGH RELATED PARTIES
(A “P53 SUBLICENSE”). P53 SHALL REMAIN RESPONSIBLE AND BE GUARANTOR OF THE PERFORMANCE BY ITS RELATED PARTIES WITH RESPECT TO A P53 SUBLICENSE AND SHALL CAUSE ITS RELATED PARTIES TO COMPLY WITH THE PROVISIONS OF THIS AGREEMENT IN
CONNECTION WITH SUCH PERFORMANCE. 
 4.4.1 IF A RELATED PARTY OF P53 SELLS PRODUCT, SUCH SALES BY THAT RELATED PARTY SHALL BE TREATED AS NET
SALES, AND ARE SUBJECT TO ROYALTIES UNDER ARTICLE 4. 
 4.4.2 IN THE EVENT OF A MATERIAL DEFAULT BY ANY RELATED PARTIES UNDER A P53
SUBLICENSE, P53 WILL PROMPTLY NOTIFY MERCK AND PROMPTLY TAKE ACTION TO REMEDY SUCH DEFAULT. 
 4.4.3 EACH AND EVERY P53 SUBLICENSE MUST BE
IN A WRITTEN AGREEMENT, IN ENGLISH, EXECUTED BY THE RELATED PARTY AND GIVING ITS PLACE OF BUSINESS. IN ADDITION, EACH AND EVERY SUCH SUBLICENSE: 

(a) MUST REQUIRE THE RELATED PARTY TO ABIDE BY CONFIDENTIALITY AND NON-USE OBLIGATIONS AT LEAST AS STRINGENT AS THOSE CONTAINED IN
ARTICLE 3 OF THIS AGREEMENT; 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

 
 8 

 C  Confidential 

 
 (b) MUST REQUIRE THE RELATED PARTY TO PAY THE ROYALTY NO LESS THAN THAT
SPECIFIED IN SECTION 4.2 OF THIS AGREEMENT AND TO KEEP RECORDS AND RENDER REPORTS AS REQUIRED IN SECTION 4.6 AND BE SUBJECT TO MERCK’S AUDIT RIGHTS AS SET FORTH IN SECTION 4.9 OF THIS AGREEMENT; 

(c) MUST OBLIGATE THE RELATED PARTY TO MAINTAIN INSURANCE IN RESPECT TO ITS ACTIVITIES PURSUANT TO ITS SUBLICENSE CONSISTENT WITH THE
OBLIGATIONS UNDER SECTION 6.4; AND 
 (d) MUST PROVIDE AN INDEMNITY FROM THE RELATED PARTY IN FAVOR OF MERCK AND MERCK INDEMNITEES TO
THE SAME EXTENT AS THE INDEMNITY CONTAINED IN SECTION 6.1, AND SPECIFICALLY PROVIDE THAT THE RELATED PARTY WILL NOT CHALLENGE THE STANDING OF MERCK IF MERCK SEEKS TO RELY ON SUCH INDEMNIFICATION. 

4.4.4 P53 WILL PROVIDE MERCK WITH PROMPT WRITTEN NOTICE IN THE EVENT THAT (A) A RELATED PARTY’S OR P53’S GOOD FAITH
MANUFACTURING AND/OR COMMERCIALIZATION EFFORTS SUBSTANTIALLY CEASES FOR A PERIOD OF AT LEAST SIX (6) MONTHS, AND/OR (B) P53 MAKES A DETERMINATION TO DISCONTINUE ITS MANUFACTURE AND/OR COMMERCIALIZATION OF PRODUCT. 

4.5 STATUS REPORTS. AT LEAST ONCE PER CALENDAR YEAR DURING THE TERM OF THIS AGREEMENT, P53 SHALL PROVIDE TO MERCK A WRITTEN STATUS
REPORT IN ENGLISH WHICH SHALL DESCRIBE THE WORLDWIDE DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF PRODUCT(S) BY P53 AND/OR ITS RELATED PARTIES. P53 SHALL RESPOND TO QUESTIONS FROM MERCK REGARDING ANY PROGRESS REPORT AND PROVIDE ADDITIONAL
RELATED INFORMATION AS REASONABLY REQUESTED BY MERCK. 
 4.6 NET SALES REPORTS; PAYMENT OF ROYALTY. FOLLOWING THE FIRST COMMERCIAL
SALE OF A PRODUCT, P53 SHALL FURNISH TO MERCK A QUARTERLY WRITTEN REPORT FOR THE CALENDAR QUARTER SHOWING THE NET SALES OF PRODUCT(S) SOLD BY P53 AND/OR ITS RELATED PARTIES IN THE TERRITORY ON A COUNTRY-BY-COUNTRY BASIS DURING THE REPORTING PERIOD
AND THE ROYALTY PAYABLE UNDER THIS AGREEMENT. REPORTS SHALL BE DUE ON THE THIRTIETH (30TH) DAY FOLLOWING THE CLOSE OF EACH CALENDAR QUARTER. ROYALTIES SHOWN TO HAVE ACCRUED BY EACH ROYALTY
REPORT SHALL BE DUE AND PAYABLE ON THE DATE SUCH ROYALTY 

  
 9 

 C  Confidential 

 
 
REPORT IS DUE. P53 SHALL KEEP COMPLETE AND ACCURATE RECORDS IN SUFFICIENT DETAIL TO ENABLE THE ROYALTIES PAYABLE HEREUNDER TO BE DETERMINED. P53 SHALL MAINTAIN SUCH RECORDS FOR NO FEWER THAN THE
MOST RECENT THREE (3) CALENDAR YEARS OR, IF LONGER, FOR ANY CALENDAR YEAR SUBJECT TO AN UNRESOLVED DISPUTE OR A PENDING AUDIT IN ACCORDANCE WITH SECTION 4.9. 

4.7 PAYMENT METHOD. ALL PAYMENTS DUE UNDER THIS AGREEMENT SHALL BE MADE BY BANK WIRE TRANSFER IN IMMEDIATELY AVAILABLE FUNDS TO SUCH
BANK ACCOUNT DESIGNATED IN WRITING BY MERCK FROM TIME-TO-TIME. ALL PAYMENTS HEREUNDER SHALL BE MADE IN U.S. DOLLARS. IN THE EVENT THAT THE DUE DATE OF ANY PAYMENT SUBJECT TO ARTICLE 4 IS A SATURDAY, SUNDAY OR NATIONAL HOLIDAY, SUCH PAYMENT MAY
BE PAID ON THE FOLLOWING BUSINESS DAY. ANY PAYMENTS THAT ARE NOT PAID ON THE DATE SUCH PAYMENTS ARE DUE UNDER THIS AGREEMENT SHALL BEAR INTEREST TO THE EXTENT PERMITTED BY APPLICABLE LAW AT THE PRIME RATE AS REPORTED BY THE BANK OF AMERICA ON THE
DATE SUCH PAYMENT IS DUE. 
 4.8 CURRENCY CONVERSION. IN THE CASE OF SALES INVOICED IN A FOREIGN CURRENCY, EXCHANGE CONVERSION OF
SUCH SALES INTO U.S. DOLLARS SHALL BE MADE ON A QUARTERLY BASIS AND SHALL BE TRANSLATED AT THE RATE OF THE AVERAGE QUARTERLY EXCHANGE QUOTES FOR THAT PERIOD AS REPORTED BY BLOOMBERG. 

4.9 AUDITS. 
 4.9.1 UPON
THE WRITTEN REQUEST OF MERCK AND NOT MORE THAN ONCE IN EACH CALENDAR YEAR, P53 SHALL PERMIT AN INDEPENDENT CERTIFIED PUBLIC ACCOUNTING FIRM OF INTERNATIONALLY RECOGNIZED STANDING SELECTED BY MERCK AND REASONABLY ACCEPTABLE TO P53, AT MERCK’S
EXPENSE, TO HAVE ACCESS DURING NORMAL BUSINESS HOURS TO SUCH OF THE RECORDS OF P53 AS MAY BE REASONABLY NECESSARY TO VERIFY THE ACCURACY OF THE ROYALTY REPORTS HEREUNDER FOR ANY CALENDAR YEAR ENDING NOT MORE THAN THIRTY-SIX (36) MONTHS PRIOR TO
THE DATE OF SUCH REQUEST. P53 SHALL ALSO CAUSE ITS RELATED PARTIES, TO THE EXTENT ANY ROYALTY PAYMENTS UNDER ARTICLE 4 ARE THE RESULT OF NET SALES OF SUCH RELATED PARTIES, TO PERMIT THE CERTIFIED PUBLIC ACCOUNTING FIRM TO HAVE ACCESS DURING
NORMAL BUSINESS HOURS TO SUCH OF THE RECORDS OF SUCH RELATED PARTIES AS MAY BE REASONABLY NECESSARY TO VERIFY THE ACCURACY OF THE ROYALTY REPORTS HEREUNDER FOR ANY SUCH CALENDAR YEAR. 

4.9.2 AUDITS CONDUCTED UNDER THIS SECTION 4.9 SHALL BE AT THE EXPENSE OF MERCK UNLESS AN UNDERPAYMENT EXCEEDING TWENTY THOUSAND DOLLARS
($20,000) OF THE ROYALTIES OWED FOR THE FULL PERIOD 

  
 10 

 C  Confidential 

 
 
COVERED BY THE AUDIT IS IDENTIFIED, IN WHICH CASE ALL FEES CHARGED BY THE ACCOUNTING FIRM SHALL BE PROMPTLY PAID BY P53. ANY UNDERPAYMENTS OR UNPAID AMOUNTS DISCOVERED BY THE AUDIT WILL BE PAID
PROMPTLY BY P53 WITH INTEREST ON SUCH AMOUNTS FROM THE DATE SUCH AMOUNT(S) WERE DUE, AT A RATE EQUAL TO THE LESSER OF THE PRIME RATE REPORTED BY BANK OF AMERICA, NEW YORK, NEW YORK PLUS TWO PERCENT (2%) PER ANNUM OR THE HIGHEST RATE PERMITTED
UNDER NEW JERSEY LAW. IN THE EVENT OF AN OVERPAYMENT BY P53, P53 SHALL BE ENTITLED TO A CREDIT ON ANY SUBSEQUENT PAYMENT DUE TO MERCK. 

4.9.3 P53 SHALL INCLUDE IN EACH SUBLICENSE GRANTED BY IT A PROVISION REQUIRING THE RELATED PARTIES TO MAKE REPORTS TO P53, TO KEEP AND
MAINTAIN RECORDS OF SALES MADE PURSUANT TO SUCH SUBLICENSE AND TO GRANT ACCESS TO SUCH RECORDS BY MERCK’S INDEPENDENT ACCOUNTANT TO THE SAME EXTENT REQUIRED OF P53 UNDER THIS AGREEMENT. 

4.9.4 UPON THE EXPIRATION OF THIRTY-SIX (36) MONTHS FOLLOWING THE END OF ANY CALENDAR YEAR, THE CALCULATION OF ROYALTIES PAYABLE WITH
RESPECT TO SUCH YEAR SHALL BE BINDING AND CONCLUSIVE UPON MERCK, AND P53 AND ITS RELATED PARTIES SHALL BE RELEASED FROM ANY LIABILITY OR ACCOUNTABILITY WITH RESPECT TO ROYALTIES FOR SUCH YEAR, UNLESS DISPUTED BY MERCK OR SUBJECT TO A PENDING AUDIT
DURING SUCH THIRTY-SIX (36) MONTH PERIOD. 
 4.9.5 MERCK SHALL TREAT ALL FINANCIAL INFORMATION SUBJECT TO REVIEW UNDER THIS
SECTION 4.9 IN ACCORDANCE WITH THE CONFIDENTIALITY PROVISIONS OF THIS AGREEMENT, AND SHALL CAUSE ITS ACCOUNTING FIRM TO RETAIN ALL SUCH INFORMATION IN CONFIDENCE. 

ARTICLE 5 REPRESENTATIONS AND WARRANTIES 

5.1 REPRESENTATIONS AND WARRANTIES OF EACH PARTY. EACH PARTY REPRESENTS AND WARRANTS TO THE OTHER PARTY THAT AS OF THE EFFECTIVE DATE:

 (A) IT HAS THE FULL RIGHT, POWER AND AUTHORITY TO ENTER INTO THIS AGREEMENT AND TO PERFORM ITS OBLIGATIONS HEREUNDER; AND 

(B) THIS AGREEMENT HAS BEEN DULY EXECUTED BY IT AND IS LEGALLY BINDING UPON IT, IS ENFORCEABLE IN ACCORDANCE WITH ITS TERMS, AND DOES NOT
CONFLICT WITH ANY AGREEMENT, INSTRUMENT OR UNDERSTANDING, ORAL OR WRITTEN, TO WHICH IT IS A PARTY OR BY WHICH IT MAY BE BOUND, NOR VIOLATE ANY MATERIAL LAW OR REGULATION OF ANY COURT, GOVERNMENTAL BODY OR ADMINISTRATIVE OR OTHER AGENCY HAVING
JURISDICTION OVER IT. 

  
 11 

 C  Confidential 

 
 5.2 MERCK REPRESENTATIONS AND WARRANTIES. MERCK REPRESENTS AND
WARRANTS TO P53 THAT AS OF THE EFFECTIVE DATE: 
 (A) IT HAS THE FULL RIGHT, POWER AND AUTHORITY TO GRANT THE LICENSE GRANTED UNDER
ARTICLE 2; AND 
 (B) TO MERCK’S KNOWLEDGE, MERCK IS THE SOLE OWNER OF THE MERCK DATA. 

5.3 COMPLIANCE WITH LAW AND ETHICAL BUSINESS PRACTICES. P53 SHALL COMPLY WITH ALL FEDERAL AND COUNTRY, STATE AND LOCAL LAWS RELATED TO
THE MANUFACTURE, DEVELOPMENT, MARKETING AND SELLING OF PRODUCT. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING SENTENCE, P53 SHALL NOT PROMOTE PRODUCT IN ANY MANNER IN CONFLICT WITH APPLICABLE LAWS AND REGULATIONS. IN ADDITION, P53 WILL USE
REASONABLE EFFORTS TO CAUSE ITS AFFILIATES AND SUBLICENSEES TO COMPLY WITH ALL SUCH LAWS AND TO PROMOTE PRODUCT CONSISTENT WITH THIS SECTION. P53 WILL PROMPTLY TAKE EFFECTIVE ACTION IN THE EVENT IT BELIEVES THAT AN AFFILIATE OR SUBLICENSEE IS NOT
COMPLYING WITH THE PRECEDING SENTENCE. 
 5.3.1 P53 ACKNOWLEDGES THAT MERCK’S CORPORATE POLICY REQUIRES THAT MERCK’S BUSINESS MUST
BE CONDUCTED WITHIN THE LETTER AND SPIRIT OF THE LAW. BY SIGNING THIS AGREEMENT, P53 AGREES TO CONDUCT ITS ACTIVITIES HEREIN IN A MANNER WHICH IS CONSISTENT WITH BOTH LAW AND GOOD BUSINESS ETHICS. 

5.3.2 NOTWITHSTANDING ANYTHING TO THE CONTRARY IN SECTION 3.1, P53 SHALL HOLD IN CONFIDENCE ALL DATA THAT IDENTIFIES OR COULD BE USED TO
IDENTIFY AN INDIVIDUAL (“PERSONAL DATA”), EXCEPT AS REQUIRED OR PERMITTED UNDER THIS AGREEMENT, OR TO THE EXTENT NECESSARY TO BE DISCLOSED TO REGULATORY AGENCIES AS PART OF THE REVIEW PROCESS. IN ADDITION, NOTWITHSTANDING ANYTHING
TO THE CONTRARY IN SECTION 3.1, P53 SHALL COMPLY WITH ALL APPLICABLE LAWS AND REGULATIONS, AS AMENDED FROM TIME TO TIME, WITH RESPECT TO THE COLLECTION, USE, STORAGE, AND DISCLOSURE OF ANY PERSONAL DATA, INCLUDING WITHOUT LIMITATION, THE U.S.
HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA) AND THE REGULATIONS PROMULGATED THEREUNDER. P53 AGREES TO ENSURE THAT ALL APPROPRIATE TECHNICAL AND ORGANIZATION MEASURES ARE TAKEN TO PROTECT PERSONAL DATA AGAINST LOSS, MISUSE, AND ANY
UNAUTHORIZED, ACCIDENTAL, OR UNLAWFUL ACCESS, DISCLOSURE, ALTERATION, OR DESTRUCTION, INCLUDING 

  
 12 

 C  Confidential 

 
 
WITHOUT LIMITATION, IMPLEMENTATION AND ENFORCEMENT OF ADMINISTRATIVE, TECHNICAL, AND PHYSICAL SECURITY POLICIES AND PROCEDURES APPLICABLE TO PERSONAL DATA. 

5.4 DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, THE MERCK DATA ARE LICENSED “AS IS”. MERCK MAKES NO
WARRANTIES WITH RESPECT TO THE MERCK DATA LICENSED HEREUNDER, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE. MERCK SPECIFICALLY DISCLAIMS ANY EXPRESS OR IMPLIED WARRANTY OF MERCHANTABILITY, OF FITNESS FOR A
PARTICULAR PURPOSE, OF DESIGN, OF ACCURACY OR VALIDITY OF THE MERCK DATA AND OF NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTIES. SUCH DISCLAIMER APPLIES TO ANY PRODUCT DEVELOPED BY P53 AS A RESULT OF P53’ USE OF THE
MERCK DATA. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, MERCK EXPRESSLY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE ACTIVITIES OF P53 PURSUANT TO THE LICENSE GRANTED HEREIN SHALL NOT INFRINGE ANY PATENT OR OTHER INTELLECTUAL PROPERTY
RIGHT OWNED BY A THIRD PARTY. 
 ARTICLE 6 INDEMNIFICATION 

6.1 INDEMNIFICATION BY P53: P53 AGREES TO INDEMNIFY, DEFEND AND HOLD HARMLESS MERCK AND ITS AFFILIATES AND THEIR RESPECTIVE OFFICERS,
DIRECTORS, EMPLOYEES AND AGENTS (COLLECTIVELY, THE “MERCK INDEMNITEES”) FROM AND AGAINST ANY AND ALL CLAIMS, SUITS, ACTIONS, DEMANDS, DAMAGES AND LIABILITIES, INCLUDING REASONABLE LEGAL COSTS AND FEES (COLLECTIVELY,
“CLAIM”), TO WHICH ANY MERCK INDEMNITEE MAY BECOME SUBJECT TO AS A RESULT OF ANY CLAIM, DEMAND, ACTION OR OTHER PROCEEDING BY ANY PERSON OR ENTITY OTHER THAN A PARTY OR ITS AFFILIATES TO THE EXTENT SUCH CLAIM ARISES DIRECTLY OR
INDIRECTLY OUT OF (A) THE BREACH BY P53 OF ANY WARRANTY, REPRESENTATION, COVENANT OR AGREEMENT MADE BY P53 IN THIS AGREEMENT, OR (B) THE DEVELOPMENT, MANUFACTURE, COMMERCIALIZATION, ADMINISTRATION, UTILIZATION AND/OR INGESTION OF ANY
PRODUCT SOLD BY P53 AND/OR ITS RELATED PARTIES; EXCEPT, IN EACH CASE, TO THE EXTENT SUCH CLAIM RESULTS FROM THE NEGLIGENCE OR WILLFUL MISCONDUCT OF ANY MERCK INDEMNITEE OR THE BREACH BY MERCK OF ANY WARRANTY, REPRESENTATION, COVENANT OR AGREEMENT
MADE BY MERCK IN THIS AGREEMENT. 
 6.2 INDEMNIFICATION BY MERCK: MERCK AGREES TO INDEMNIFY, DEFEND AND HOLD HARMLESS P53, AND ITS
AFFILIATES AND THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS (COLLECTIVELY, THE “P53 INDEMNITEES”) FROM AND AGAINST ANY AND ALL CLAIM TO WHICH ANY P53 INDEMNITEE MAY BECOME SUBJECT TO AS A RESULT OF ANY CLAIM BY ANY

  
 13 

 C  Confidential 

 
 
PERSON OR ENTITY OTHER THAN A PARTY OR ITS AFFILIATES TO THE EXTENT SUCH CLAIM ARISES DIRECTLY OR INDIRECTLY OUT OF THE BREACH BY MERCK OF ANY REPRESENTATION MADE BY MERCK IN SECTION 5.2;
EXCEPT TO THE EXTENT SUCH CLAIM RESULTS FROM THE NEGLIGENCE OR WILLFUL MISCONDUCT OF ANY P53 INDEMNITEE OR THE BREACH BY P53 OF ANY WARRANTY, REPRESENTATION, COVENANT OR AGREEMENT MADE BY P53 IN THIS AGREEMENT. 

6.3 INDEMNIFICATION PROCEDURES. IN THE EVENT THAT ANY INDEMNITEE IS SEEKING INDEMNIFICATION UNDER SECTIONS 6.1 OR 6.2 ABOVE FROM A
PARTY (THE “INDEMNIFYING PARTY”), THE OTHER PARTY SHALL NOTIFY THE INDEMNIFYING PARTY OF SUCH CLAIM WITH RESPECT TO SUCH INDEMNITEE AS SOON AS REASONABLY PRACTICABLE AFTER THE INDEMNITEE RECEIVES NOTICE OF THE CLAIM, AND THE PARTY
(ON BEHALF OF ITSELF AND SUCH INDEMNITEE) SHALL PERMIT THE INDEMNIFYING PARTY TO ASSUME DIRECTION AND CONTROL OF THE DEFENSE OF THE CLAIM (INCLUDING THE RIGHT TO SETTLE THE CLAIM SOLELY FOR MONETARY CONSIDERATION) AND SHALL COOPERATE AS REQUESTED
(AT THE EXPENSE OF THE INDEMNIFYING PARTY) IN THE DEFENSE OF THE CLAIM. THE INDEMNIFICATION OBLIGATIONS UNDER ARTICLE 6 SHALL NOT APPLY TO ANY HARM SUFFERED AS A DIRECT RESULT OF ANY DELAY IN NOTICE TO THE INDEMNIFYING PARTY HEREUNDER OR TO
AMOUNTS PAID IN SETTLEMENT OF ANY CLAIM IF SUCH SETTLEMENT IS EFFECTED WITHOUT THE CONSENT OF THE INDEMNIFYING PARTY, WHICH CONSENT SHALL NOT BE WITHHELD OR DELAYED UNREASONABLY. THE INDEMNITEE, ITS EMPLOYEES AND AGENTS, SHALL REASONABLY COOPERATE
WITH THE INDEMNIFYING PARTY AND ITS LEGAL REPRESENTATIVES IN THE INVESTIGATION OF ANY CLAIM COVERED BY SECTIONS 6.1 AND 6.2. 
 6.4
INSURANCE. AT SUCH TIME AS P53 OR ANY RELATED PARTY BEGINS TO SELL OR DISTRIBUTE PRODUCT(S), P53 OR SUCH RELATED PARTY, AS THE CASE MAY BE, SHALL, AT ITS OWN EXPENSE, PROCURE AND MAINTAIN POLICIES OF COMPREHENSIVE GENERAL LIABILITY INSURANCE
(INCLUDING WITHOUT LIMITATION PRODUCT LIABILITY INSURANCE) IN THE MINIMUM AMOUNT OF TWENTY MILLION DOLLARS ($20,000,000). A P53’S RELATED PARTY MAY MEET THIS OBLIGATION THROUGH SELF-INSURANCE PROGRAMS OF COMPARABLE COVERAGE, PROVIDED THAT SUCH
RELATED PARTY IS (A) A PUBLICLY TRADED COMPANY, AND (B) HAS A MOODYS OR S&P INVESTMENT GRADE RATING. ALL SUCH INSURANCE BY P53 AND EACH OF ITS RELATED PARTIES SHALL BE PRIMARY WITHOUT ANY CONTRIBUTION BY MERCK’S INSURANCE. ALL
SUCH POLICIES SHALL NAME MERCK AS AN ADDITIONAL INSURED. ANY DEDUCTIBLES OR RETENTIONS SHALL BE THE RESPONSIBILITY, AS THE CASE MAY BE, OF P53 OR ITS RELATED PARTY. UPON MERCK’S REQUEST, P53 WILL PROMPTLY PROVIDE FOR ITSELF AND EACH OF ITS
RELATED PARTIES’ COPIES OF CERTIFICATES OF INSURANCE EVIDENCING SUCH COVERAGES. P53 

  
 14 

 C  Confidential 

 
 
SHALL NOTIFY MERCK, NOT LESS THAN THIRTY (30) DAYS IN ADVANCE OF ANY MATERIAL CHANGE OR CANCELLATION OF ANY SUCH POLICY. P53 SHALL CONTINUE AND SHALL REQUIRE EACH OF ITS RELATED PARTY TO
MAINTAIN SUCH INSURANCE AFTER THE EXPIRATION OR TERMINATION OF THIS AGREEMENT DURING ANY PERIOD IN WHICH P53 OR ITS RELATED PARTY CONTINUES TO MAKE, HAVE MADE, USE, SELL, OFFER TO SELL OR IMPORT PRODUCT AND FOR A PERIOD OF NOT LESS THAN FIVE
(5) YEARS AFTER P53 AND EACH OF ITS RELATED PARTIES HAS CEASED ALL COMMERCIAL SALE, DISTRIBUTION OR USE OF ANY PRODUCT. P53 HEREBY WAIVES AND WILL CAUSE EACH OF ITS RELATED PARTIES TO WAIVE RIGHTS OF SUBROGATION AGAINST MERCK. 

ARTICLE 7 TERM AND TERMINATION 

7.1 TERM AND EXPIRATION. THIS AGREEMENT SHALL BE EFFECTIVE AS OF THE EFFECTIVE DATE AND UNLESS TERMINATED EARLIER PURSUANT TO
SECTIONS 2.3, 7.2 AND 7.3, THIS AGREEMENT SHALL CONTINUE IN EFFECT UNTIL EXPIRATION OF ALL ROYALTY OBLIGATIONS HEREUNDER. 
 7.2
TERMINATION FOR CAUSE. THIS AGREEMENT MAY BE TERMINATED AT ANY TIME DURING THE TERM OF THIS AGREEMENT: 
 7.2.1 UPON WRITTEN NOTICE
BY EITHER PARTY IF THE OTHER PARTY IS IN BREACH OF ITS MATERIAL OBLIGATIONS HEREUNDER BY CAUSES AND REASONS WITHIN ITS CONTROL AND HAS NOT CURED SUCH BREACH OR SHOWN SUCH BREACH TO BE NON-EXISTENT WITHIN THIRTY (30) DAYS AFTER NOTICE REQUESTING
CURE OF THE BREACH; OR 
 7.2.2 IMMEDIATELY BY EITHER PARTY UPON THE FILING OR INSTITUTION OF BANKRUPTCY, REORGANIZATION, LIQUIDATION OR
RECEIVERSHIP PROCEEDINGS, OR UPON AN ASSIGNMENT OF A SUBSTANTIAL PORTION OF THE ASSETS FOR THE BENEFIT OF CREDITORS BY THE OTHER PARTY, PROVIDED, HOWEVER, THAT IN THE CASE OF ANY INVOLUNTARY BANKRUPTCY PROCEEDING SUCH RIGHT TO
TERMINATE SHALL ONLY BECOME EFFECTIVE IF THE PARTY CONSENTS TO THE INVOLUNTARY BANKRUPTCY OR SUCH PROCEEDING IS NOT DISMISSED WITHIN NINETY (90) DAYS AFTER THE FILING THEREOF. 

7.3 RIGHT TO TERMINATE. P53 SHALL HAVE THE RIGHT TO TERMINATE THIS AGREEMENT (I) IMMEDIATELY UPON THE OCCURRENCE OF THE EVENT
DESCRIBED IN SECTION 2.3, AND (II) UPON NINETY (90) DAYS’ PRIOR WRITTEN NOTICE AT ANY TIME AFTER NINE (9) MONTHS OF THE EFFECTIVE DATE. 

  
 15 

 C  Confidential 

 
 7.4 EFFECT OF TERMINATION; SURVIVING OBLIGATIONS. 

7.4.1 UPON TERMINATION BY P53 PURSUANT TO SECTION 7.2.1: 

(a) THE LICENSE GRANTED BY MERCK TO P53 UNDER SECTION 2.1 SHALL SURVIVE SUCH TERMINATION, TOGETHER WITH P53’ OBLIGATIONS TO PAY
ROYALTIES REQUIRED UNDER ARTICLE 4; PROVIDED, THAT THE AMOUNT OF SUCH ROYALTIES AM) MILESTONE PAYMENTS SHALL BE REDUCED BY [***] ([***]%) OF THE AMOUNTS SET FORTH IN ARTICLE 4 ON AND AFTER SUCH DATE; 

(b) EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS SECTION 7.4, THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT SHALL
TERMINATE AS OF THE DATE OF SUCH TERMINATION. 
 7.4.2 UPON TERMINATION BY MERCK PURSUANT TO SECTION 7.2 OR BY P53 PURSUANT TO
SECTION 7.3: 
 (a) THE LICENSE GRANTED BY MERCK TO P53 UNDER SECTION 2.1 SHALL AUTOMATICALLY TERMINATE; 

(b) EACH P53 SUBLICENSE SHALL CONTINUE AND EACH SUCH P53 SUBLICENSEE SHALL BE CONSIDERED A DIRECT LICENSEE OF MERCK, PROVIDED THAT
(I) SUCH RELATED PARTY IS THEN IN FULL COMPLIANCE WITH ALL TERMS AND CONDITIONS OF ITS SUBLICENSE, (II) ALL ACCRUED PAYMENTS OBLIGATIONS TO MERCK HAVE BEEN PAID, AND (III) SUCH RELATED PARTY AGREES IN WRITING TO ASSUME ALL OBLIGATIONS OF P53
UNDER THIS AGREEMENT INCLUDING ALL FINANCIAL OBLIGATIONS OF P53; 
 (c) P53 SHALL, WITHIN THIRTY (30) DAYS AFTER THE EFFECTIVE DATE OF
SUCH TERMINATION, RETURN OR CAUSE TO BE RETURNED TO MERCK ALL INFORMATION IN TANGIBLE FORM; 
 (d) P53 SHALL IMMEDIATELY NOTIFY ALL RELATED
PARTIES OF TERMINATION OF THIS AGREEMENT; 
 (e) EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN SECTION 7.4, THE RIGHTS AND OBLIGATIONS OF
THE PARTIES UNDER THIS AGREEMENT TERMINATE AS OF THE DATE OF SUCH TERMINATION. 

  

	***	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions 

 
 16 

 C  Confidential 

 
 7.4.3 EXPIRATION OR TERMINATION OF THIS AGREEMENT SHALL NOT RELIEVE THE
PARTIES OF ANY OBLIGATION ACCRUING PRIOR TO SUCH EXPIRATION OR TERMINATION. ANY EXPIRATION OR TERMINATION OF THIS AGREEMENT SHALL BE WITHOUT PREJUDICE TO THE RIGHTS OF EITHER PARTY AGAINST THE OTHER ACCRUED OR ACCRUING UNDER THIS AGREEMENT PRIOR TO
EXPIRATION OR TERMINATION, INCLUDING THE OBLIGATION TO PAY ROYALTIES FOR PRODUCT(S) SOLD PRIOR TO SUCH EXPIRATION OR TERMINATION. THE PROVISIONS OF ARTICLE 1, SECTION 2.2, SECTION 2.3, ARTICLE 3, SECTION 4.6,
SECTION 4.9, ARTICLE 5, ARTICLE 6, SECTION 7.4, ARTICLE 8, SHALL SURVIVE THE EXPIRATION OR TERMINATION OF THIS AGREEMENT. 

ARTICLE 8 MISCELLANEOUS 

8.1 FORCE MAJEURE. 

8.1.1 NEITHER PARTY SHALL BE HELD LIABLE TO THE OTHER PARTY NOR BE DEEMED TO HAVE DEFAULTED UNDER OR BREACHED THIS AGREEMENT FOR FAILURE OR
DELAY IN PERFORMING ANY OBLIGATION UNDER THIS AGREEMENT TO THE EXTENT SUCH FAILURE OR DELAY IS CAUSED BY OR RESULTS FROM CAUSES BEYOND THE REASONABLE CONTROL OF THE AFFECTED PARTY, POTENTIALLY INCLUDING EMBARGOES, WAR, ACTS OF WAR (WHETHER WAR BE
DECLARED OR NOT), ACTS OF TERRORISM, INSURRECTIONS, RIOTS, CIVIL COMMOTIONS, STRIKES, LOCKOUTS OR OTHER LABOR DISTURBANCES, FIRE, FLOODS, OR OTHER ACTS OF GOD, OR ACTS, OMISSIONS OR DELAYS IN ACTING BY ANY GOVERNMENTAL AUTHORITY OR THE OTHER PARTY,
BUT IF AND ONLY IF THE PARTY AFFECTED SHALL HAVE USED REASONABLE EFFORTS TO AVOID SUCH OCCURRENCE. THE AFFECTED PARTY SHALL NOTIFY THE OTHER PARTY OF SUCH FORCE MAJEURE CIRCUMSTANCES AS SOON AS REASONABLY PRACTICAL, AND SHALL PROMPTLY UNDERTAKE ALL
REASONABLE EFFORTS NECESSARY TO CURE SUCH FORCE MAJEURE CIRCUMSTANCES. 
 8.1.2 NOTHING IN THIS SECTION 8.1 SHALL EXCUSE P53 FROM
MAKING TIMELY PAYMENTS AS REQUIRED BY THIS AGREEMENT. 
 8.1.3 ANY NON-PERFORMANCE OR DELAY OF P53 SUBJECT TO THIS SECTION 8.1 THAT IS
IN EXCESS OF THREE (3) MONTHS WILL CONSTITUTE CAUSE FOR TERMINATION UNDER SECTION 7.2.1 (WITHOUT, HOWEVER, ANY FURTHER CURE OR NOTICE PERIOD AS PROVIDED UNDER SECTION 7.2.1) UPON WRITTEN NOTICE BY MERCK TO P53. 

8.2 ASSIGNMENT. P53 MAY NOT ASSIGN ITS RIGHTS OR OBLIGATIONS UNDER THIS AGREEMENT WITHOUT THE PRIOR WRITTEN CONSENT OF MERCK.

  
 17 

 C  Confidential 

 
 
ANY ATTEMPTED ASSIGNMENT NOT IN ACCORDANCE WITH THIS SECTION 8.2 SHALL BE VOID; PROVIDED, HOWEVER, THAT EITHER PARTY MAY, WITHOUT THE WRITTEN CONSENT OF THE OTHER, ASSIGN THIS AGREEMENT AND
ITS RIGHTS AND DELEGATE ITS OBLIGATIONS HEREUNDER TO ITS AFFILIATES, OR IN CONNECTION WITH THE TRANSFER OR SALE OF ALL OR SUBSTANTIALLY ALL OF SUCH PARTY’S ASSETS OR BUSINESS RELATED TO THIS AGREEMENT, OR IN THE EVENT OF A CHANGE OF CONTROL.
ANY PERMITTED ASSIGNEE SHALL ASSUME ALL ASSIGNED OBLIGATIONS OF ITS ASSIGNOR UNDER THIS AGREEMENT. MERCK MAY FREELY ASSIGN THIS AGREEMENT AND ANY RIGHTS AND OBLIGATIONS HEREUNDER. A “CHANGE OF CONTROL” MEANS WITH RESPECT TO A PARTY:
(1) THE SALE OF ALL OR SUBSTANTIALLY ALL OF SUCH PARTY’S ASSETS OR BUSINESS RELATING TO THIS AGREEMENT; (2) A MERGER, REORGANIZATION OR CONSOLIDATION INVOLVING SUCH PARTY IN WHICH THE VOTING SECURITIES OF SUCH PARTY OUTSTANDING
IMMEDIATELY PRIOR THERETO CEASE TO REPRESENT AT LEAST FIFTY PERCENT (50%) OF THE COMBINED VOTING POWER OF THE SURVIVING ENTITY IMMEDIATELY AFTER SUCH MERGER, REORGANIZATION OR CONSOLIDATION; OR (3) A PERSON OR ENTITY, OR GROUP OF PERSONS
OR ENTITIES, ACTING IN CONCERT ACQUIRE MORE THAN FIFTY PERCENT (50%) OF THE VOTING EQUITY SECURITIES OR MANAGEMENT CONTROL OF SUCH PARTY. 

8.3 SEVERABILITY. IF ANY ONE OR MORE OF THE PROVISIONS CONTAINED IN THIS AGREEMENT IS HELD INVALID, ILLEGAL OR UNENFORCEABLE IN ANY
RESPECT, THE VALIDITY, LEGALITY AND ENFORCEABILITY OF THE REMAINING PROVISIONS CONTAINED HEREIN SHALL NOT IN ANY WAY BE AFFECTED OR IMPAIRED THEREBY, UNLESS THE ABSENCE OF THE INVALIDATED PROVISION(S) ADVERSELY AFFECTS THE SUBSTANTIVE RIGHTS OF THE
PARTIES. THE PARTIES SHALL IN SUCH AN INSTANCE USE THEIR BEST EFFORTS TO REPLACE THE INVALID, ILLEGAL OR UNENFORCEABLE PROVISIONS) WITH VALID, LEGAL AND ENFORCEABLE PROVISION(S) WHICH, INSOFAR AS PRACTICAL, IMPLEMENT THE PURPOSES OF THIS AGREEMENT.

 8.4 NOTICES. ANY NOTICES REQUIRED OR PROVIDED BY THE TERMS OF THIS AGREEMENT SHALL BE IN WRITING, ADDRESSED IN ACCORDANCE WITH
THIS PARAGRAPH, AND SHALL BE DELIVERED, EXCEPT AS OTHERWISE INDICATED BELOW, PERSONALLY OR SENT BY CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED, POSTAGE PREPAID OR BY NATIONALLY-RECOGNIZED EXPRESS COURIER SERVICES PROVIDING EVIDENCE OF
DELIVERY. EXCEPT AS NOTED BELOW, THE EFFECTIVE DATE OF ANY NOTICE SHALL BE THE DATE OF FIRST RECEIPT BY THE RECEIVING PARTY. NOTICES SHALL BE SENT TO THE ADDRESS(ES)/ADDRESSEE(S) GIVEN BELOW OR TO SUCH OTHER ADDRESS(ES)/ADDRESSEE(S) AS THE PARTY TO
WHOM NOTICE IS TO BE GIVEN MAY HAVE PROVIDED TO THE OTHER PARTY IN WRITING IN ACCORDANCE WITH THIS PROVISION. 

  
 18 

 C  Confidential 

 
  

			
	if to P53, to:	  	P53 Inc.
		  	2000 Edwards Street
		  	Houston, TX 77007
		  	Attn: [Robert E. Sabot, MD]
		
	if to Merck, to:	  	Merck Sharp & Dohme Corp.
		  	One Merck Drive
		  	P.O. Box 100, WS3A-65
		  	Whitehouse Station, NJ 08889-0100
		  	Attention: Office of Secretary
		
	And	  	Merck Sharp & Dohme Corp.
		  	351 North Sumneytown Pike
		  	P.O. Box 1000
		  	North Wales, PA 19454-2505
		  	Attention: Dr. Roger Pomerantz, Sr. VP Licensing

 8.5 APPLICABLE LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS
OF THE STATE OF NEW JERSEY WITHOUT REFERENCE TO ANY RULES OF CONFLICT OF LAWS. 
 8.6 DISPUTE RESOLUTION. 

8.6.1 THE PARTIES SHALL NEGOTIATE IN GOOD FAITH AND USE REASONABLE EFFORTS TO SETTLE ANY DISPUTE, CONTROVERSY OR CLAIM ARISING FROM OR RELATED
TO THIS AGREEMENT OR THE BREACH THEREOF. IF THE PARTIES DO NOT FULLY SETTLE, AND A PARTY WISHES TO PURSUE THE MATTER, EACH SUCH DISPUTE, CONTROVERSY OR CLAIM SHALL BE FINALLY RESOLVED BY BINDING ARBITRATION IN ACCORDANCE WITH THE COMMERCIAL
ARBITRATION RULES AND SUPPLEMENTARY PROCEDURES FOR LARGE COMPLEX DISPUTES OF THE AMERICAN ARBITRATION ASSOCIATION (“AAA”), AND JUDGMENT ON THE ARBITRATION AWARD MAY BE ENTERED IN ANY COURT HAVING JURISDICTION THEREOF. 

8.6.2 THE ARBITRATION SHALL BE CONDUCTED BY A PANEL OF THREE PERSONS EXPERIENCED IN THE PHARMACEUTICAL BUSINESS: WITHIN THIRTY (30) DAYS
AFTER INITIATION OF ARBITRATION, EACH PARTY SHALL SELECT ONE PERSON TO ACT AS ARBITRATOR AND THE TWO PARTY-SELECTED ARBITRATORS SHALL SELECT A THIRD ARBITRATOR WITHIN THIRTY (30) DAYS OF THEIR APPOINTMENT. IF THE ARBITRATORS SELECTED BY THE
PARTIES ARE UNABLE OR FAIL TO AGREE UPON THE THIRD ARBITRATOR, THE THIRD ARBITRATOR SHALL BE APPOINTED BY THE AAA. THE PLACE OF ARBITRATION SHALL BE NEW YORK, NEW YORK, AND ALL PROCEEDINGS AND COMMUNICATIONS SHALL BE IN ENGLISH. 

  
 19 

 C  Confidential 

 
 8.6.3 EITHER PARTY MAY APPLY TO THE ARBITRATORS FOR INTERIM INJUNCTIVE
RELIEF UNTIL THE ARBITRATION AWARD IS RENDERED OR THE CONTROVERSY IS OTHERWISE RESOLVED. EITHER PARTY ALSO MAY, WITHOUT WAIVING ANY REMEDY UNDER THIS AGREEMENT, SEEK FROM ANY COURT HAVING JURISDICTION ANY INJUNCTIVE OR PROVISIONAL RELIEF NECESSARY
TO PROTECT THE RIGHTS OR PROPERTY OF THAT PARTY PENDING THE ARBITRATION AWARD. THE ARBITRATORS SHALL HAVE NO AUTHORITY TO AWARD PUNITIVE OR ANY OTHER TYPE OF DAMAGES NOT MEASURED BY A PARTY’S COMPENSATORY DAMAGES. EACH PARTY SHALL BEAR ITS OWN
COSTS AND EXPENSES AND ATTORNEYS’ FEES AND AN EQUAL SHARE OF THE ARBITRATORS’ FEES AND ANY ADMINISTRATIVE FEES OF ARBITRATION. 

8.6.4 EXCEPT TO THE EXTENT NECESSARY TO CONFIRM AN AWARD OR AS MAY BE REQUIRED BY LAW, NEITHER A PARTY NOR AN ARBITRATOR MAY DISCLOSE THE
EXISTENCE, CONTENT, OR RESULTS OF AN ARBITRATION WITHOUT THE PRIOR WRITTEN CONSENT OF BOTH PARTIES. IN NO EVENT SHALL AN ARBITRATION BE INITIATED AFTER THE DATE WHEN COMMENCEMENT OF A LEGAL OR EQUITABLE PROCEEDING BASED ON THE DISPUTE, CONTROVERSY
OR CLAIM WOULD BE BARRED BY THE APPLICABLE NEW JERSEY STATUTE OF LIMITATIONS. 
 8.7 ENTIRE AGREEMENT; AMENDMENTS. THIS AGREEMENT,
TOGETHER WITH ANY ATTACHMENTS HERETO, CONTAINS THE ENTIRE UNDERSTANDING OF THE PARTIES WITH RESPECT TO THE SUBJECT MATTER HEREOF AND SUPERCEDES AND CANCELS ALL PREVIOUS EXPRESS OR IMPLIED AGREEMENTS AND UNDERSTANDINGS, NEGOTIATIONS, WRITINGS AND
COMMITMENTS, EITHER ORAL OR WRITTEN, IN RESPECT TO THE SUBJECT MATTER HEREOF. EACH ATTACHMENT TO THIS AGREEMENT IS INCORPORATED HEREIN BY REFERENCE AND SHALL BE DEEMED A PART OF THIS AGREEMENT. IN THE EVENT OF CONFLICT BETWEEN THIS AGREEMENT AND ANY
ATTACHMENT, THIS AGREEMENT SHALL CONTROL. THIS AGREEMENT MAY BE AMENDED, OR ANY TERM HEREOF MODIFIED, ONLY BY A WRITTEN INSTRUMENT DULY EXECUTED BY AUTHORIZED REPRESENTATIVES OF BOTH PARTIES. 

8.8 HEADINGS. THE CAPTIONS TO THE SEVERAL ARTICLES, SECTIONS AND SUBSECTIONS HEREOF ARE NOT A PART OF THIS AGREEMENT, BUT ARE MERELY
FOR CONVENIENCE TO ASSIST IN LOCATING AND READING THE SEVERAL ARTICLES AND SECTIONS HEREOF. 
 8.9 INDEPENDENT CONTRACTORS. IT IS
EXPRESSLY AGREED THAT MERCK AND P53 SHALL BE INDEPENDENT CONTRACTORS AND THAT THE RELATIONSHIP BETWEEN THE TWO PARTIES SHALL NOT CONSTITUTE A PARTNERSHIP, JOINT VENTURE OR AGENCY. NEITHER MERCK NOR P53 SHALL HAVE THE AUTHORITY TO MAKE ANY
STATEMENTS, REPRESENTATIONS OR COMMITMENTS OF ANY KIND, OR TO TAKE ANY ACTION, WHICH SHALL BE BINDING ON THE OTHER PARTY, WITHOUT THE PRIOR WRITTEN CONSENT OF THAT PARTY. 

  
 20 

 C  Confidential 

 
 8.10 WAIVER. THE WAIVER BY EITHER PARTY OF ANY RIGHT HEREUNDER,
OR OF ANY FAILURE OF THE OTHER PARTY TO PERFORM, OR OF ANY BREACH BY THE OTHER PARTY, SHALL NOT BE DEEMED A WAIVER OF ANY OTHER RIGHT HEREUNDER OR OF ANY OTHER BREACH BY OR FAILURE OF SUCH OTHER PARTY WHETHER OF A SIMILAR NATURE OR OTHERWISE. 

8.11 CUMULATIVE REMEDIES. NO REMEDY REFERRED TO IN THIS AGREEMENT IS INTENDED TO BE EXCLUSIVE, BUT EACH SHALL BE CUMULATIVE AND IN
ADDITION TO ANY OTHER REMEDY REFERRED TO IN THIS AGREEMENT OR OTHERWISE AVAILABLE UNDER LAW. 
 8.12 WAIVER OF RULE OF CONSTRUCTION.
EACH PARTY HAS HAD THE OPPORTUNITY TO CONSULT WITH COUNSEL IN CONNECTION WITH THE REVIEW, DRAFTING AND NEGOTIATION OF THIS AGREEMENT. ACCORDINGLY, THE RULE OF CONSTRUCTION THAT ANY AMBIGUITY IN THIS AGREEMENT SHALL BE CONSTRUED AGAINST THE DRAFTING
PARTY SHALL NOT APPLY. 
 8.13 CERTAIN CONVENTIONS. ANY REFERENCE IN THIS AGREEMENT TO AN ARTICLE, SECTION, SUBSECTION, PARAGRAPH,
CLAUSE, OR SCHEDULE SHALL BE DEEMED TO BE A REFERENCE TO AN ARTICLE, SECTION, SUBSECTION, PARAGRAPH, CLAUSE, OR SCHEDULE, OF OR TO, AS THE CASE MAY BE, THIS AGREEMENT, UNLESS OTHERWISE INDICATED. UNLESS ‘FHA CONTEXT OF THIS AGREEMENT OTHERWISE
REQUIRES, (A) WORDS OF ANY GENDER INCLUDE EACH OTHER GENDER, (B) WORDS SUCH AS “HEREIN”, “HEREOF”, AND “HEREUNDER” REFER TO THIS AGREEMENT AS A WHOLE AND NOT MERELY TO THE PARTICULAR PROVISION IN WHICH SUCH
WORDS APPEAR, (C) WORDS USING THE SINGULAR SHALL INCLUDE THE PLURAL, AND VICE VERSA, (D) THE WORDS “INCLUDE,” “INCLUDES” AND “INCLUDING” SHALL BE DEEMED TO BE FOLLOWED BY THE PHRASE “BUT NOT LIMITED
TO”, “WITHOUT LIMITATION”, “INTER ALIA” OR WORDS OF SIMILAR IMPORT; AND (E) THE WORDS “SHALL” AND “WILL” ARE USED INTERCHANGEABLY WITHOUT INTENDED DISTINCTION AND EACH WORD IS USED TO CONVEY A
MANDATORY OBLIGATION. 
 8.14 BUSINESS DAY REQUIREMENTS. IF ANY NOTICE OR OTHER ACTION OR OMISSION IS REQUIRED TO BE TAKEN BY A PARTY
UNDER THIS AGREEMENT ON A DAY THAT IS NOT A BUSINESS DAY, THEN SUCH NOTICE OR OTHER ACTION OR OMISSION IS REQUIRED TO BE TAKEN ON THE NEXT OCCURRING BUSINESS DAY. 

8.15 COUNTERPARTS. THIS AGREEMENT MAY BE SIGNED IN ANY NUMBER OF COUNTERPARTS (FACSIMILE AND ELECTRONIC TRANSMISSION INCLUDED), EACH OF
WHICH SHALL BE DEEMED AN ORIGINAL, BUT ALL OF 

  
 21 

 C  Confidential 

 
 
WHICH SHALL CONSTITUTE ONE AND THE SAME INSTRUMENT EVEN IF BOTH PARTIES HAVE NOT EXECUTED THE SAME COUNTERPART. AFTER FACSIMILE OR ELECTRONIC TRANSMISSION, THE PARTIES AGREE TO EXECUTE AND
EXCHANGE DOCUMENTS WITH ORIGINAL SIGNATURES. 
 IN WITNESS WHEREOF, THE PARTIES HAVE EXECUTED THIS AGREEMENT AS OF THE EFFECTIVE
DATE. 
  

									
	P53 INC.	 		 	MERCK SHARP & DOHME CORP.
					
	BY:	 	 /s/ Robert E. Sobol
	 		 	BY:	 	 /s/ Roger Pomerantz

	[Signature]	 		 	[Signature]
					
	NAME:	 	 Robert E. Sobol, MD
	 		 	NAME:	 	 Roger Pomerantz

	[Print]	 		 	[Print]
					
	TITLE:	 	 President and CEO
	 		 	TITLE:	 	 SVP WW Licensing & Acquisitions and Knowledge Management

					
	DATE:	 	 8-1-2012
	 		 	DATE:	 	 8/8/12

  
 22 

 C  Confidential 

 
 Attachment A 

Merck Data 
  

	1.	Gene Therapy of Primary and Metastatic Malignant Tumors of the Liver Using SCH 58500 (RAD/P53) Via Hepatic Artery Infusion: A Phase I Study (Protocol C95-063). 

 

	2.	A Phase 2 Study of SCH 058500 in Combination with Chemotherapy and chemotherapy alone in patients with colorectal cancer metastatic to the liver (Protocol C98-118). 

  
 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00242-of-00352.parquet"}]]